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Abstract 
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by 
multi-organ damage. There is a strong evidence for genetics playing an important role in 
the development of disease. Genetic association studies have begun to identify many 
SLE-associated genetic loci, yet for very few of these loci is the specific pathogenic 
mechanism of disease described. We undertook a genetic fine-mapping study of the 
PXK locus, which our group had previously identified as being associated with SLE. In 
the course of performing the fine-mapping study, we also developed a streamlined 
analytic approach. By using existing genetic analysis software suites, linking them with 
small Linux scripts and parallel processing multiple statistical models simultaneously, 
we were able to greatly facilitate our genetic analysis. For the PXK locus, we identify a 
257kb haplotype associated with SLE. The strongest association was found at 
rs6445972 with P < 4.62 × 10−10, OR 0.81 (0.75–0.86). We confirmed this finding with 
Bayesian analysis, confirming a 95% credible set consisting of 172 variants. We found 
one association at the locus. In addition to the genetic fine-mapping results, we also 
demonstrate that PXK colocalizes with the B cell antigen receptor (BCR) following BCR-
crosslinking. shRNA-mediated knockdown of PXK resulted in delayed BCR 
internalization. Cell lines derived from patients carrying the SLE-associated risk variant 
displayed a delay in BCR internalization. Given the role for BCR internalization in B cell 
fate determination and survival, our results support new candidate mechanisms for SLE-
disease risk, including BCR trafficking and BCR-mediated B cell activation. 
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Selected Genetic Definitions 
Minor allele frequency (MAF)- The frequency at which the less common allele occurs 
at a specific genomic position. 
Hardy-Weinberg equilibrium (HWE)- Simply stated, allele frequencies in a population 
should remain constant from generation to generation in the absence of outside 
pressures. Deviations from HWE can be estimated within a genetic dataset, identifying 
potential bias within the data. 
Bayes Factor (BF)- Used in Bayesian statistics, it is a measure of the relative evidence 
in the data. 
Posterior probability- A measure of the probability in Bayesian statistics of the 
conditional probability of a random event after accounting for background information. 
Single nucleotide polymorphism (SNP)- A DNA sequence variation at a single 
genomic position that varies within the population as a whole. 
Linkage disequilibrium (LD)- The non-random association of alleles at a genetic 
locus. LD is a measure of the probability that a given allele will be inherited in tandem 
with another specified allele. 
Imputation- A statistical genetic technique used to fill in missing genotyping data by 
comparing the genotype of a specific individual with the genotypes of a control cohort. 
Using the frequency of known genotypes of the control group permits a “best guess” 
approach to filling the missing genotypes of the specific individual. 
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Genome wide association study (GWAS)- A genetic association study using 
genotype information from generally a large, unbiased selection of genotyped SNPs 
across the entire genome. 
Conditional analysis- A method to identify the specific influence of a given allele on the 
dataset as a whole, by including the genotype at that allele as a covariate in the overall 
analysis.		
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Chapter 1: Background and Introduction 
 
The overarching theme of the immune system is balance. Our immune system 
recognizes and reacts to potentially harmful stimuli, whether a pathogenic virus, such as 
the flu, or a mutated cell that is no longer identified as being a part of our “self”. At the 
same time, it also recognizes but tolerates the food and myriad of commensal 
organisms that colonize our bodies. After recognition of something dangerous, a finely 
balanced series of signals leads to neutralization of the threat. The virus is killed, as are 
those cells that harbor it. The mutated cell is destroyed, averting the potential cancer. 
Importantly, following the elimination of the specific threat, the immune system is 
restored to its basal level. This restoration occurs through a finely tuned series of steps.  
This balance, this homeostasis, is the key to our survival and maintenance of health. 
Fundamentally, autoimmunity occurs as a consequence of the loss of 
homeostasis. Sometimes this occurs within an isolated organ system, such as the 
thyroid as in Hashimoto’s thyroiditis- the immune system targets the cells of the thyroid, 
leading to loss of thyroid function and subsequently, disease. This loss of balance can 
also occur on a system wide level, as occurs in Systemic Lupus Erythematous (SLE) or 
lupus, in which widespread immune activation leads to multiple organ damage and 
chronic disease. In this introduction, I will describe and compare a few of the various 
forms of autoimmunity, specifically focusing on lupus. 
 
General principles of autoimmunity 
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There is both direct and indirect evidence for autoimmunity. Throughout this 
dissertation, autoimmunity is defined as an immune response directed against self. This 
definition is important because we consider autoimmunity as a primary driver of disease. 
Strong evidence that autoimmunity is a primary disease process and not an 
epiphenomenon is the transfer of antibody resulting in disease. A prime example of this 
is maternal-fetal transfer of antibody where the transfer of a mother’s autoantibodies to 
her fetus results in disease, such as in Grave’s disease (GD) [1], myasthenia gravis 
(MG) [2], lupus (leading to both dermatologic and cardiac disease in the infant)[3] and 
Sjogren’s (SS)[4]. Direct disruptions of healthy processes mediated by autoantibodies 
can also be observed in vitro as demonstrated by disruptions of the coagulation 
cascade. Both cold agglutinins and antiphospholipid (aPL) antibodies are capable of this 
disruption. Cold agglutinins, autoantibodies directed against polysaccharide complexes 
found on the surface of red blood cells, can be isolated from a patient’s blood and 
hemolysis measured in vitro. aPL antibodies are directed against blood proteins 
involved in coagulation [5, 6]. The presence of these antibodies is predictive of an 
increase of thrombotic events. The aPL antibodies can be detected in vitro by a 
prolongation of the clotting times in coagulations assays. 
Indirect evidence of the autoimmune response as a primary mediator of disease 
is found in animal models of human autoimmune diseases; either through recapitulation 
in animal models following immunization with suspected causal antigen, or through 
naturally occurring disease. Examples of the former include autoimmune thyroiditis in 
mice [7, 8] and the experimental autoimmune encephalomyelitis (EAE) mouse model of 
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multiple sclerosis (MS) [9]. Naturally occurring disease in mice include those with lupus-
like phenotypes (NZB/NZW [10, 11], MRL/lpr [12], BXSB [13]) and the diabetic NOD 
mouse [14]. 
Finally, circumstantial evidence supports the autoimmune disease process as 
well. The presence of autoantibodies is an important aspect of the differential diagnosis, 
but natural autoantibodies are common. Family history can be an important factor as 
autoimmunity does run in families. Autoimmune disorders also demonstrate clear 
gender bias, with autoimmunity overall occurring more often in females than males. 
Within the spectrum of individual autoimmune diseases however, there is more variation 
which can be useful in diagnosis, as SS occurs only 5% of the time in men, while 
ulcerative colitis (UC) and diabetes mellitus (DM) have a fairly even male to female 
distribution [15]. The autoimmune reaction as a primary mediator of disease is thus 
supported by multiple pieces of evidence. 
 
Autoantibodies in autoimmunity 
As discussed above, autoantibodies are a common feature of some autoimmune 
diseases and are often a first step in the diagnosis. Autoantibodies cause disease by 
multiple mechanisms. Broadly, they can act in a similar capacity to regular antibodies, 
as facilitators of antigen processing and presentation by antigen presenting cells (APCs) 
via opsonization, or to activate the complement cascade. Autoantibody binding and 
subsequent opsonization are important steps in the phagocyte-dependent presentation 
of nuclear antigens [16] and in the maintenance of the autoimmune response in immune 
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thrombocytopenic purpura (ITP) [17]. Immune complex binding by the complement 
protein C1q is the first step of the classical complement activation pathway. As 
autoantibodies also form immune complexes (ICs), it is no surprise that they also can 
activate the complement cascade. Complement binding to ICs links the innate and 
adaptive immune responses. The presence of complement during antigen presentation 
to B cells lowers the activation threshold [18].  
 For most autoimmune diseases, even though there is strong evidence that 
autoantibodies are important in the pathogenesis of disease, actual demonstration of 
autoantibodies having a causal role in disease pathogenesis is rare. Anti-glomerular 
basement membrane (anti-GBM) disease is one of the few exceptions. The 
Goodpasture antigen is directed against type IV collagen. Antibody binding leads to 
severe GBM damage and involves complement activation as demonstrated by C3 
deposition [19, 20]. 
 In addition to the traditional functions of antibodies, autoantibodies directed 
against receptors can also have a functional impact on receptor signaling. In GD, 
autoantibodies target the TSH receptor resulting in receptor activation and subsequent 
hyperthyroidism [21]. Myasthenia gravis (MG) is an autoimmune disease marked by 
autoimmune mediated disruption of the neuromuscular junction that results in increasing 
muscle weakness and fatigability. In MG, autoantibodies both block receptor signaling 
and fix complement, leading to receptor degradation. Binding of autoantibodies to the 
acetylcholine receptor (AChR) results in receptor blockade [22]. As the disease 
progresses, a significant reduction of AChR from the neuromuscular junction is 
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observed as a result of complement mediated destruction. Autoantibodies can thus 
have both direct and indirect involvement in autoimmune disease pathogenesis and are 
not present solely as an incidental byproduct of an autoimmune inflammatory reaction. 
 
Systemic Lupus Erythematosus: Clinical findings 
A diagnosis of lupus requires a patient to meet 4 of 11 criteria as defined by the 
American College of Rheumatology (ACR) [23, 24], see Table 1. The wide range of 
possible symptoms underscores the heterogeneous nature of lupus. These criteria do 
not necessarily need to occur simultaneously and often symptoms wax and wane over 
the course of the disease. The main symptoms of lupus as experienced by the patient 
can be divided into two groups- constitutional symptoms and those that relate to organ 
specific involvement. The frequencies of various manifestations are outlined in Table 2. 
The main constitutional symptoms are fatigue, myalgia, fever and weight loss. All are 
very common in lupus, with estimates ranging from 50-100% of patients experiencing 
these constitutional symptoms. While constitutional symptoms are very common in 
lupus, they are also very non-specific. 
 
Table 1: ACR criteria for the clinical diagnosis of SLE. 
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Criterion Definition 
1. Malar rash Fixed erythema, flat or raised, over the malar eminences, tending to spare the 
nasolabial folds 
2. Discoid rash Erythematous raised patches with adherent keratotic scaling and follicular plugging; 
atrophic scarring may occur in older lesions 
3. Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient history or physician 
observation 
4. Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by physician 
5. Arthritis Nonerosive arthritis involving 2 or more peripheral joints, characterized by 
tenderness, swelling, or effusion 
6. Serositis 
a) Pleuritis--convincing history of pleuritic pain or rubbing heard by a physician or 
evidence of pleural effusion 
  OR 
  b) Pericarditis--documented by ECG or rub or evidence of pericardial effusion 
7. Renal disorder 
a) Persistent proteinuria greater than 0.5 grams per day or grater than 3+ if 
quantitation not performed 
  OR 
  b) Cellular casts--may be red cell, hemoglobin, granular, tubular, or mixed 
8. Neurologic 
disorder 
a) Seizures--in the absence of offending drugs or known metabolic derangements; 
e.g., uremia, ketoacidosis, or electrolyte imbalance 
  OR 
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b) Psychosis--in the absence of offending drugs or known metabolic derangements, 
e.g., uremia, ketoacidosis, or electrolyte imbalance 
9. Hematologic 
disorder 
a) Hemolytic anemia--with reticulocytosis 
  OR 
  b) Leukopenia--less than 4,000/mm3 total on 2 or more occasions 
  OR 
  c) Lyphopenia--less than 1,500/mm3 on 2 or more occasions 
  OR 
  d) Thrombocytopenia--less than 100,000/mm3 in the absence of offending drugs 
10. Immunologic 
disorder 
a) Positive LE cell preparation 
  OR 
  b) Anti-DNA: antibody to native DNA in abnormal titer 
  OR 
  c) Anti-Sm: presence of antibody to Sm nuclear antigen 
  
OR 
  
d) False positive serologic test for syphilis known to be positive for at least 6 months 
and confirmed by Treponema pallidum immobilization or fluorescent treponemal 
antibody absorption test 
11. Antinuclear 
antibody 
An abnormal titer of ANA by immunofluorescence or an equivalent assay at any point 
in time and in the absence of drugs known to be associated with "drug-induced lupus" 
syndrome 
4 of 11 criteria are required, either sequentially or simultaneously, for a clinical diagnosis of SLE. Table 
adapted from Tan et al., Arthritis Rheum. 1982 [23], and Hochberg, Arthritis Rheum,1997 [24]. 
 
Table 2: Frequency of selected manifestations of lupus 
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Manifestation Frequency (%) 
Constitutional symptoms (fatigue, fever, weight loss) 90-95 
Mucocutaneous involvement (malar rash, alopecia, mucosal ulcers, discoid 
lesions, etc.) 80-90 
Musculoskeletal involvement (arthritis/arthralgia, avascular necrosis, myositis, 
etc.) 80-90 
Serositis (pleuritis, pericarditis, peritonitis) 50-70 
Glomerulonephritis 40-60 
Neuropsychiatric involvement (cognitive impairment, depression, psychosis, 
seizures, stroke, demyelinating syndromes, peripheral neuropathy, etc.) 40-60 
Autoimmune cytopenia (anemia, thrombocytopenia) 20-30 
The varied manifestations of lupus and their respective frequencies underscore the heterogeneous aspect 
of this disease. Table adapted from Dall’Era et al., Kelley’s Textbook of Rheumatology, 2013 [317]. 
 
 Organ specific manifestations of lupus can also be shared amongst many 
diseases, especially other autoimmune diseases. This underscores the importance of 
the ACR criteria, as it is the unique combination of organ system involvement and 
laboratory findings that support the diagnosis of lupus. Most organ systems can be 
involved in some way or another in lupus and will be reviewed briefly below.  
Joint symptoms including inflammatory arthritis are very common and often part 
of the clinical picture at initial presentation. Lupus arthritis is rarely deforming, in contrast 
with rheumatoid arthritis (RA), which often leads to sever joint erosion and deformation 
[25, 26]. 
Another of the most common clinical findings at initial presentation is involvement 
of the skin. The most common rash of lupus is the butterfly rash, marked by erythema 
on the cheeks and nose sparing the nasolabial folds. More severe discoid lesions can 
also occur and lead to scaring. Alopecia is also common [27]. Oral and nasal 
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mucocutaneous lesions also occur and tend to be less painful than those associated 
with Herpes simplex [28]. The Raynaud phenomenon, blanching or cyanosis of distal 
skin as a result of vasoconstriction in response to cold temperature, particularly in the 
digits of the hands and feet, is also common. Again, the Raynaud phenomenon is not 
lupus specific as it can occur both primarily and secondarily, especially in relation to 
other connective tissue diseases and scleroderma. 
Kidney involvement is very common, with 40-60% estimates of lifetime 
occurrence in lupus patients, with renal disease being one of the major factors in the 
long-term morbidity and mortality in SLE. Immune complex-mediated glomerulonephritis 
is the most common form of kidney involvement [29]. Due to the high prevalence of 
kidney disease and the potential for severe complications, close monitoring of renal 
health is recommended [14, 30]. The presence of kidney disease is usually indicative of 
a poorer outcome [31]. 
The gastrointestinal tract can be involved both primarily from lupus itself, or more 
commonly, secondarily due to medication side effects. Non-steroidal anti-inflammatory 
drugs (NSAIDs) and glucocorticoids, both commonly used in lupus, have significant 
gastrointestinal (GI) side effects, including dyspepsia and peptic ulcers. Dysphagia is 
the most common GI complaint in lupus. Decreased peristalsis in the esophagus is the 
most frequent cause and can occur in both SLE and scleroderma, though SLE rarely 
affects the lower esophageal sphincter, which is common in scleroderma [32]. 
The most common pulmonary symptom is pleuritis but can also include pleural 
effusions, chronic interstitial lung disease, pulmonary arterial hypertension and others. 
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aPL antibodies are associated with thromboembolic lesions in the lungs. Dyspnea is a 
common complaint with clinical findings of abnormal pulmonary function tests consistent 
with restrictive abnormalities. The most common cardiovascular manifestations of lupus 
include pericarditis and valvular abnormalities such as valvular thickening and 
regurgitation. In addition, patients with lupus are at increased risk for coronary artery 
disease. aPL antibodies are also associated with coronary artery thrombosis. 
Neurologic involvement can range from neuropsychiatric symptoms such as 
depression to neurosensory disruption like peripheral neuropathy [33]. The precise 
pathogenesis is often unknown. Neurological disease in lupus can be roughly divided 
into vascular in origin or inflammatory in origin. aPL antibodies are associated with CNS 
thromboembolic events [34]. Inflammation can lead to increased permeability of the 
blood-brain barrier, cytokine production, etc. Clinical manifestations of neurologic 
involvement in lupus include cognitive dysfunction such as difficulty in thinking, memory 
and concentration [35, 36]. Additionally psychosis, depression and anxiety can all occur 
in patients with lupus [37, 38]. Specific nerve involvement can occur as in MS, including 
optic neuritis and myelitis. Autoantibodies suggestive of lupus plus other relevant history 
can help differentiate the two. Peripheral neuropathy can also occur [39]. The most 
common ophthalmologic complaint is keratoconjunctivitis sicca (KCS), which often 
occurs with secondary SS [40]. 
 Hematologic disruptions are common in lupus, most commonly cytopenias 
including leukopenia, anemia and thrombocytopenia [41]. Anemia is most often anemia 
of chronic disease but autoimmune hemolytic anemia also occurs. Leukopenia can be 
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primary or secondary as a result of medication, especially glucocorticoids. 
Thrombophilia can occur most often in the context of aPL antibodies, though advanced 
kidney disease can also increase the risk of thromboembolic events [42]. Peripheral 
lymphadenopathy is another common finding [43]. Vasculitis can occur in SLE with 
presentation dependent upon localization of the lesion [44].  
 
Autoantibodies in lupus 
The prototypical immunological finding in lupus is the production of 
autoantibodies. Autoantibodies are a distinctive feature of many autoimmune diseases, 
however, and do not provide direct evidence of autoimmunity as they can be found both 
in healthy individuals [45] and prior to overt symptomology in lupus [46], RA, 
antiphospholipid syndrome, and type I diabetes mellitus, though in the later case they 
may be highly predictive of disease [47]. 
The most common autoantibodies in lupus are the anti-nuclear antibodies (Table 
3). These are autoantibodies targeting nuclear components of the cell and are highly 
sensitive for lupus; over 95% of SLE patients are ANA positive. The antibodies are 
detected in a fairly unique manner for a clinical test, as HEp-2 cells, a human epithelial 
cell line, are treated with dilutions of serum from patients where a positive test is 
indicated by a nuclear distribution of immunostaining [48-50]. ANAs are not as specific, 
however, as ANAs can also be positive in RA, scleroderma, polymyositis, SS, and are 
also found in healthy controls [51, 52]. Following a positive ANA result, patients are 
usually screened for further autoantibodies. Anti-Sm is one of the most specific for 
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autoantibodies for lupus, with a specificity of 98% [53], with anti-dsDNA used most 
commonly for confirmation. 
 
Table 3: Common autoantibodies in lupus. 
Antigen Specificity Prevelance (%) ANA? Main Clinical effects 
Anti-double-stranded 
DNA 70-80 Yes Kidney disease, skin disease 
Nucleosomes 60-90 Yes Kidney disease, skin disease 
Ro 30-40 Yes Skin disease, kidney disease, fetal heart problems 
La 15-20 Yes Fetal heart problems 
Smith (Sm) 10-30 Yes Kidney disease 
NMDA receptor 33-50 No Brain disease 
Phospholipids 20-30 No Thrombosis, pregnancy loss 
α-actinin 20 No Kidney disease 
C1q 40-50 No Kidney disease 
Chart of the most frequent autoantibodies in lupus detailing their prevalence, whether or not they are 
antinuclear, and the main clinical effects with which they are associated. Adapted from Rahman and 
Isenberg, NEJM, 2008 [54]. References: dsDNA: [55-57], Nucleosomes: [58], Ro: [59], [60], La: [59], Sm 
[61], NMDA receptor: [62], [63], phospholipids: [64], α-actinin: [65], [66], C1q: [67]. 
 
 
The generation of auto-reactive clones during lymphocyte development, in both B 
and T cell pools, is common. Upward of 50% of BCR/TCR rearrangements are 
responsive to self-antigen [68-70]. Given the high rate of autoreactive lymphocyte 
production, yet the low overall rate of autoimmune disease prevalence of less than 5% 
[71], it is apparent that the immune system is able to fine-tune the lymphocyte 
repertoire. Four general mechanisms for limiting the impact of autoreactive clones have 
been described [72]: 1) Eliminate cells with a self-reactive receptor. 2) Edit the self-
 13 
reactive receptor. 3) Alter the responsiveness of the self-reactive cell through gene 
expression or other cell-intrinsic changes. 4) Limit the availability of outside help (such 
as co-stimuli, growth factors, etc.), reducing the ability of self-reactive clones to activate 
in the periphery. The relevance of this model to understanding the pathogenesis of 
lupus is evidenced by the examples from both mouse models and human disease of 
disruption of each of these pathways leading to autoimmunity and in many cases either 
lupus or a lupus-like disease. The MRL-lpr, or Faslpr mice clearly demonstrate the 
consequences of the failure to eliminate self-reactive lymphocytes. These mice develop 
severe lymphoproliferation and a lupus-like phenotype due to a mutation in the Fas 
gene, preventing apoptotic elimination of self-reactive lymphocytes [73-75]. 
Homozygous lpr mice have a more severe phenotype than the background MRL mice, 
which still have a late autoimmune syndrome [76]. Crossing the lpr mutation onto 
congenic inbred strains resulted in autoantibody production, but in a less severe overall 
phenotype [76]. This suggests that lpr/fas contributes to autoimmune disease, but that 
the background genetic environment also significantly contributes to disease 
pathogenesis [77, 78]. While there are further examples of disruptions of elimination of 
self-reactive lymphocytes leading to autoimmunity, including Bim deficient mice 
developing autoantibodies [79], and mutations in AIRE leading to autoimmune 
polyendocrine syndrome (APECED), a severe autoimmune disorder [80, 81], there is 
little evidence for a failure in receptor editing leading to autoimmunity. Interestingly, T 
cells are primary mediators in APECED [82], but B cells play a critical role in regulating 
the T cell response [83] with limited support for rituximab as a potential treatment option 
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[84]. Thus it seems that most of the regulation of autoimmune clones falls on the cell-
intrinsic and cell-extrinsic tuning mechanisms. 
 
B cells as targets for lupus therapies 
B cells have been a main focus of new lupus therapy development. Belimumab, 
an anti-BAFF therapy targeting B cell development was the first new drug approved by 
the FDA for the treatment of lupus in over 50 years [85]. Belimumab has been shown to 
reduce autoantibody titers, reduced plasma cell numbers without greatly effecting 
memory B cells or T cell populations [86]. There is evidence that belimumab was 
effective in treating lupus associated renal disease, although patients with advanced 
disease were excluded [87]. Further study is obviously needed. Results with rituximab, a 
chimeric monoclonal antibody that targets CD20 positive cells, have been mixed. While 
some earlier studies suggested that rituximab may be efficacious in lupus [88-94] and 
rituximab has been shown to reduce overall B cell numbers in patients with lupus, lupus 
nephritis remained unchanged [95]. The later finding may be a consequence of study 
design [96], as meta-analysis of existing data supports rituximab as an effective in lupus 
nephritis [97]. Another treatment that initially showed promised was an anti-CD154 
antibody. Treatment with anti-CD154 resulted in a decrease in activated B cells in 
patients with lupus and also a reduction in serum autoantibodies, proteinuria and overall 
lupus severity. The trial was stopped though as there was also an increase in thrombotic 
events [98]. 
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B cell development  
B cells arise from hematopoietic progenitors in the bone marrow and fetal liver. 
The BCR is the fundamental distinguishing feature of the B cell and the development 
and diversification of the BCR lies at the heart of B cell development [99, 100]. The BCR 
consists structurally of heavy and light chains encoded by the V, D and J gene 
segments in the H chain locus and V and J gene segments in the L chain locus. The 
diverse repertoire of BCRs produced arises from the ordered rearrangement of these 
segments [101-105]. The heavy chain is assembled first during the pro-B cell stage. 
Following rearrangement of the H chain locus, the newly transcribed heavy chain is 
paired with a surrogate light chain to form the pre-BCR [106, 107]. This surface 
expression of this receptor marks the pre-B cell stage of B cell development. 
Underscoring the central role of BCR signaling to B cell development and survival, only 
pre-B cells with functional heavy chains (those capable of signaling when paired with 
the surrogate light chain) proceed with rearrangement of the L chain locus. Those that 
fail this checkpoint undergo additional rounds of H chain rearrangement until either a 
functional heavy chain is produced or until the cell is eliminated [108]. Following 
successful rearrangement of the L chain locus and functional heavy/light chain pairing 
the BCR+ immature B cell leaves the bone marrow and enters the periphery en route to 
the spleen or other peripheral lymphoid organs where further maturation occurs. During 
this period between emergence from the bone marrow and subsequent maturation, the 
immature B cells are known as transitional B cells [109]. 
 
 16 
Transitional B cells and lupus 
 The Ig locus gives rise to the various Ig classes, including IgM, IgD, IgG, IgA and 
IgE. During maturation in the bone marrow, surface-bound IgM is the first class to be 
expressed. (This stage of B cell development culminating in functional IgM expression is 
also known as the antigen independent stage). Transitional B cells continue to express 
IgM along with low levels of IgD. There are two main subsets of transitional B cells: T1 
and T2. These subsets are found in both mice and humans and can be distinguished by 
CD21/CD24 expression amongst CD19+IgM+ cells [110]. In the context of lupus and 
BCR signaling, transitional B cell are interesting in that they appear to be uniquely 
sensitive to BCR crosslinking and may mark an important step in B cell selection. T1 
cells appear to be more susceptible to BCR-induced apoptosis than T2 cells in vitro 
[111, 112], which may be due to T2-specific rescue from apoptosis [113]. 
 Transitional B cells are more abundant in blood from patients with lupus [114, 
115]. This difference was found to be independent of absolute numbers, suggesting 
bone marrow production was normal [115]. This increase is not associated with disease 
activity [109]. In fact, transitional B cells are also increased in immunocompromised 
individuals including those with X-linked immunoproliferative disorder (XLP) [116]. The 
exact role of transitional B cells in lupus requires further research, but provides further 
evidence of the disruption in homeostasis underlying lupus [117]. 
 
Genetic and environmental factors in lupus pathogenesis 
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 Given the heterogeneous nature of lupus, it is not the breakdown or loss of a 
single mechanism or system that leads to disease, but instead is most likely a result of 
the interaction of multiple factors in concert that result in the breakdown of homeostasis 
and subsequent overt manifestations of disease. The exact pathophysiological cause of 
lupus is still unknown, but various contributing factors have been or are just now 
beginning to be identified and will be discussed below. These potential causal factors 
can be broken down into two broad categories, namely environmental and genetic. 
 Environmental factors for the purpose of this discussion constitute those agents 
that are external in nature and include chemical exposure and infectious agents. 
Multiple environmental factors have been investigated as having a role in lupus 
pathogenesis including smoking, therapeutic drugs, UV exposure, EBV (which is 
discussed in Chapter 2), and uranium exposure. Cigarette smoking has been 
associated with both the development of SLE [118] and disease activity [119]. A study in 
a Japanese population suggests that this relationship may be due to differential 
production of reactive oxygen species [120]. 
Various drugs have been found to induce a lupus-like disease in patients 
including procainamide, hydralazine, minocycline and TNF-alpha therapy. Overall, 
symptoms of drug-induced lupus are similar to SLE and include fever, myalgia, rash, 
arthralgia and arthritis. The exact pathogenesis of drug-induced lupus remains 
unknown, but the underlying pathology appears to be very similar to SLE as they share 
many of the same features. Serological abnormalities are common, with autoantibodies, 
especially anti-ANA, occurring frequently. Thrombocytopenia and elevated gamma 
 18 
globulins are also common. Interestingly, the lupus-inducing drugs are highly diverse 
with few structural similarities. In addition, the drugs are largely inert; there is no 
evidence that a specific property of the chemical compound causes lupus. Finally, drug-
induced lupus occurs weeks or months after treatment initiation, yet the lupus-inducing 
drugs reach steady state quite rapidly. These observations have lead to the hypothesis 
that altered drug metabolism is responsible for drug-induced lupus.  
UV exposure is known to induce or exacerbate lupus skin lesions [121]. UV light 
acts on keratinocytes to secrete inflammatory cytokines including IL-1, IL-3, IL-6, GM-
CSF and TNF-alpha [122, 123]. UV-induced apoptosis of keratinocytes causes 
autoantigens to cluster in blebs near the cell surface. These autoantigen-containing 
structures could presumably be a source for subsequent re-exposure leading to clinical 
flares [124]. 
 Chemical and industrial exposures have also been found to increase the risk of 
lupus, including silica exposure [125] and uranium exposure [126]. Other chemical and 
industrial exposures such as mercury and hydrocarbons show some evidence of 
association and are the subject of further research [127]. 
 
Statistical strategies to genetic association testing 
Recent advances in genetic analysis have provided further support of the genetic 
underpinnings of SLE pathogenesis. This is reviewed more thoroughly in my published 
review from 2012 [128], included as chapter 2 of this dissertation. The following section 
will develop selected themes more specifically. 
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The underlying hypothesis of genetic association studies is that these associated 
variants serve as markers for actual causal variants. One of the basic ways to test this 
hypothesis statistically is with a chi-square test. Using the chi-square formula Χ! =
(!"#$%&$' !"#$%!!"#$%&$' !"#$%)(!"#$%&$' !"#$%) !, we can calculate the difference between the observed 
and expected distribution of alleles at each variants. Under the null hypothesis, we 
expected the same allelic distribution at a given variant in both cases and controls. 
While this model allows us to quickly calculate a p value for the difference in allele 
distribution between cases and controls, is limited as we cannot introduce covariates 
into the model to account for some of the other potential differences between our 
groups, including ancestral makeup. While efforts are made to select populations as 
closely matched as possible, there is 
still the possibility that the case 
population has an underlying difference 
from the controls that will influence the 
chi-square distribution, confound the 
results. 
One way to control for these 
differences in study populations is by 
calculating population substructure, or 
admixture, and adding this variable to 
the model. Admixture is the measure of 
the different ancestral population 
Figure 1: Plot of first two principal compo-
nents in individuals reporting European 
ancestry.
Results of principle component analysis depicting plot 
of first two principle components, revealing population 
substructure derived from underlying genetic similari-
ties and differences. Individuals that have more 
genetic substructure in common are clustered 
together. Outliers represent individuals with significant 
differences from the rest of the group, and are circled 
in red.
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makeup of an individual’s genome [129, 130]. Two common ways by which this is done 
is through principal component analysis (PCA) and by direct admixture calculation. 
Principal component analysis calculates eigenvectors for each sample in the population 
[131]. These data can then be viewed on a scatterplot, giving a visual confirmation of 
underlying substructure. This analysis can be repeated multiple times, giving multiple 
principal components for each sample (Figure 1). These principal components are then 
taken into account in the final model, allow the model to control for whatever underlying 
structure exists. Similar to PCA, admixture can be directly calculated by using ancestral 
informative markers (AIMs), which have been validated to be able to distinguish 
between different ancestral populations. These AIMs are genotyped as part of the study, 
then admixture values are calculated for each ancestry of interest for each individual. In 
this manner, underlying admixture can be directly calculated for each sample in the 
study population. 
As chi-square analysis does not permit the introduction of the admixture 
estimates in the association model, logistic regression is commonly used in association 
analysis. Logistic regression allows for the inclusion of additional covariates in the 
statistical model, including admixture estimates as described above. This permits a 
more accurate analysis, accounting for the potential error introduced by population 
stratification that may otherwise lead to false positives. 
 
PXK 
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As the focus of my dissertation work is PXK, the following section briefly reviews 
the gene and protein. PXK encodes a PX domain containing serine/threonine kinase. It 
was first described in 2005 based on homology with other PX domain containing 
proteins [132]. The PX domain, or Phox-homology domain, was first identified in 
NADPH oxidase [133] and has been found to be a common motif especially in the 
sorting nexin (SNX) family of proteins [134, 135]. The PX domain interacts primarily with 
phosphoinositides, in particular phosphotidylinositol-3-phosphate (PI3P) [134], though 
the PX domain has also been shown to participate in protein-protein interactions as well 
[136]. PX domain proteins participate in a number of signaling and membrane-
associated cellular activities including endosomal membrane sorting [137], controlling 
intercellular trafficking [138, 139], and trafficking of receptors into endosomes [140]. In 
addition to the PX domain, PXK also contains a region with high homology to a 
serine/threonine protein kinase domain. However, there are key highly conserved 
residues in ser/thr-protein kinases that are non-conserved in PXK. In addition, no kinase 
activity was detected when tested, suggesting that PXK is a dead kinase [141].  
 The function of PXK remains largely unexplored. Takeuchi et al provided the first 
experimental examination of the functional role of PXK [141]. They found that PXK 
localized to the endosomal membrane in COS-7 cells, and that site-directed 
mutagenesis of the PX domain or inhibition of PI3K with wortmannin completely 
eliminated this colocalization. Additionally, they showed that the presence of PXK 
accelerated the internalization and subsequent degradation of EGFR. PXK depletion 
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resulted in reduced internalization of the EGFR, most notably at the earliest time points, 
with a correction toward normal at later time points [141].  
 Our group first identified the PXK locus as a lupus-associated locus in 2008 
[142]. Since that time, it has been confirmed as a lupus-associated locus [143], [144] 
and as a susceptibility locus in systemic sclerosis [145] and RA [146]. In each of these 
studies, the association was limited to individuals of Caucasian descent. Multiple studies 
have looked in particular at Asian populations, but have not found an association 
between overall SLE occurrence and the PXK locus [147, 148], though the former did 
identify an association between the PXK locus and autoantibody production [147]. While 
we were preparing our manuscript for publication, another group published a smaller 
fine mapping of study of the PXK locus [149]. This study confirms the genetic 
association with lupus in the locus, but focuses on another gene in the region, ABHD6, 
as being the causal gene. I will explore these findings and their conclusions further in 
both my published manuscript that follows, and in the discussion section at the 
conclusion of this dissertation. In summary, we found that there is a strong, single 
genetic association with lupus at the PXK locus. In addition, we found that PXK 
colocalizes with the BCR and that PXK knockdown resulted in delayed internalization of 
the BCR. 
• PXK encodes a PX domain containing ser/thr kinase with critical non-
conservation in the kinase domain. 
• PXK is a member of the SNX family of proteins and has been found to regulate 
internalization of receptors. 
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• Variants in the PXK locus are associated with lupus, RA, and systemic sclerosis. 
 
Of the specific lupus associated loci discussed above, my graduate work is 
focused on the PXK locus. I approached this locus from two directions simultaneously; 
from a genetic analysis standpoint, and from biological perspective. The next section is 
our review of the current state of lupus genetics. The following section is a presentation 
of the analytical strategies and tools we utilized to undertake a fine mapping of the PXK 
locus and other loci in our group as well. Our overall strategy was refined considerably 
over the past few years. I then present the published manuscript that presents the 
results of both our fine-mapping study and the biological studies focused on the impact 
of the SLE-associated genetic signal on PXK function within the B cell.   
 
 
  
 24 
Chapter 2: Genetic Susceptibility to Lupus: the 
biological basis of genetic risk found in B cell signaling 
pathways 
 
Introduction 
Systemic lupus erythematosus (SLE or lupus) is an archetypical systemic 
autoantibody-mediated autoimmune disease. Autoantibody production in lupus leads to 
direct autoantibody-target tissue damage and to indirect autoantibody-autoantigen 
(immune) complex formation and deposition, both resulting in multisystem tissue injury. 
Lupus is highly variable both in severity and in the range of clinical manifestations, as 
evidenced by allowing classification as lupus with any combination of 4 of 11 criteria 
[23, 24]. 
Lupus is ten-fold more frequent in women and three- to seven-fold more frequent 
in non-European ancestries [150]. Despite its heterogeneity, SLE has a strong genetic 
component, with heritability estimates as high as 66%, a high sibling risk ratio (8-29), 
and a concordance rate in monozygotic twins (~30%) ten times higher than that of 
dizygotic twins (~3%) [151]. The most powerful evidence for a genetic component for 
lupus susceptibility, however, is the approximately 50 genetic variants that are now 
convincingly established to be associated with lupus (Table 4). In aggregate, these 
independent associations account for a minor fraction of the genetic risk of lupus [151], 
suggesting that other risk factors and better models of genetic effect remain to be 
discovered. 
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Table 4: Genes Associated with Lupus 
Gene Location Odds Ratio 
Best 
p-value population References 
SNP with 
best p value 
(Risk allele) 
Ref 
MAF 
of 
Best 
SNP 
Causal variant 
(minor allele) 
PTPN22 1p13.2 1.35 3.4 x10-12 EU, HA [152-155] 
rs2476601 
(A) 
[154] 
0.10 rs2476601 (A) PTPN22 R620W 
FCGR2A, 
FCGR3B 1q23 1.59 9.1x10
-7* EU, AA, AS 
[153, 156-
160] 
rs1801274 
(T) 
[153] 
0.43 rs1801274 (T) FCGR2A H166R 
NCF2 1q25 1.19 1.01x10-54 
EU, 
AS,AA, 
HA 
[154, 161-
165] 
rs17849502 
(G) 
[165] 
0.12 
rs17849502 (G) 
NCF2 H389Q 
 
rs17849501 (T) 
NCF2 A202A 
CRP 1q23.2 0.49 9.2x10-14 EU, AA [166] 
rs3093061 
(G) 
[166] 
0.19  
TNFSF4 1q25 1.46 2.5x10-32 EU, AS, HA 
[153, 154, 
162, 167-
169] 
rs2205960 
(T) 
[168] 
0.35  
IL10 1q31-q32 1.19 4.0x10-8 EU, AA, AS 
[154, 170-
172] 
rs3024505 
(A) 
[154] 
0.16 
Elk-1 preferentially 
binds lupus-risk 
allele rs3122605 (G) 
C1q 
C1r, C1s  
C2, C4  
1p36 
12p13 
6p21.3 
 
Convincing 
Family 
Studies* 
EU [173-177]   
Multiple, usually 
gene product 
deficiencies 
TET3 2p13.1 0.75 6.9x10-17 AS [178] 
rs6705628 
(C) 
[178] 
0.05  
RASGRP3 2p25.1-24.1 0.7 1.3 x10
-15 AS [168] 
rs13385731 
(C) 
[168] 
0.13  
IFIH1 2q2113512204 1.11 1.6 x10
-8 EU, AA 
[164, 179, 
180] 
 
 
rs13023380 
(G) 
[180] 
0.75 
rs10930046  
IFIH1 R460H 
 
rs1990760 
IFIH1 A946T 
 
rs13023380 (A) 
reduces the affinity 
efficiency of nuclear 
extract binding 
STAT4/STAT1 2q32.2-q32.3 1.55 5.17x10
-42 EU, AA, 
AS, HA 
[153, 162, 
167, 181-
187] 
rs7582694 
(C ) 
[168] 
0.42  
CD80 
3q13.3-
q21 
 
0.79 2.5x10-16 AS [168] 
rs6804441 
(A) 
[168] 
0.31  
PXK 3p14.3 1.25 7.1 x10-9 EU 
[153, 162, 
169, 185, 
188] 
rs6445975 
(C ) 
[153] 
0.32  
TREX1 3p21.31 44.65 8.5x10-11 EU [189, 190] 
rs3135945 
(A) 
[189] 
0.01 
TREX1 R11H and 
others 
(all uncommon or 
rare) 
TMEM39A 3q13.33 0.72 8.62×10−9 EU, AS [191] 
rs1132200 
(A) 
[191] 
0.01  
AFF1 4q21 0.81 8.3×10-9 AS [186] 
rs340630 
(A) 
[186] 
0.44  
BANK1 4q24 1.3 2.642x10-13 EU, AA, AS, HA 
[162, 167, 
192, 193] 
rs10516487 
(A) 0.13 
rs10516487 (A) 
BANK1 R61H 
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[193] 
IL2/IL21 4q26-q27 0.86 2.2 x10-8 EU, AA, AS 
[161, 194, 
195] 
rs907715 
(G) 
[194] 
0.31  
TNIP1 5q32-q33.1 1.27 3.8x10
-13 EU, AA, AS 
[154, 162, 
168, 196-
198] 
rs7708392 
(G) 
[153] 
0.45  
PTTG1 5q35.1 1.22 1x10-10 EU [153, 199] 
rs2431697 
(C) 
[153] 
0.38  
MIR146a 5q34 1.29 2.74x20-8 AA, AS, EU [199-201] 
rs57095329 
(G) 
[200] 
0.21 
rs57095329 affects 
binding of Ets1 to 
the promoter 
HLA and other 
genes 6p21.3 2.35 1.27x10
-51 EU, AS, 
AA, HA 
[153-155, 
162, 168, 
186, 196, 
197, 200, 
202-205] 
rs1270942 
(G[153] 0.2  
ATG5 6q21 1.25 5.2x10-12 EU, AS [153, 154, 162, 168] 
rs548234 
(G) 
[168] 
0.33 
 
 
 
 
 
 
 
UHRF1BP1 
 
6p21 1.49 44x10-9 EU, AS [154, 206] 
rs13205210 
(C) 
[206] 
0.18 
rs11755393 
UHRF1BP1 R454Q 
 
rs13205210 
 UHRF1BP1 
M1098T 
TNFAIP3 6q23 1.72 1.3x10-17 EU, AA, AS 
[154, 162, 
168, 186, 
207-210] 
rs2230926 
(C ) 
[168] 
0.07 
TT>A polymorphic 
dinucleotide; 
decreased NFκB 
binding by inhibiting 
DNA looping 
facilitated by NF-kB 
and SATB1 
HIP1 7q11.23 1.43 1.3x10-8 AS [186] 
rs6964720 
(A) 
[186] 
0.25  
IKZF1 7p12.2 0.72 2.8 x 10-23 AS, EU [162, 164, 168, 198] 
rs4917014 
(A) 
[168] 
0.25  
JAZF1 7p15.2-p15.1 1.19 1.5 x 10
-9 EU [154, 162] 
rs849142 
(T) 
[154] 
0.49  
IRF5/TNPO3 7q32 1.54 3.611x10-19 EU, AA, AS, HA 
[153-155, 
162, 211-
214] 
rs12537284 
(A) 
[153] 
0.19 
Independent 
variants reduce IRF5 
activity 
XKR6 8p23.1 0.81 2.5x10-11 EU [153, 155] 
rs6985109 
(G) 
[153] 
0.49  
BLK 8p23-p22 0.69 2.1x10-24 EU, AA, AS, HA 
[153, 168, 
186, 215-
217] 
rs7812879 
(A) 
[168] 
0.12  
LYN 8q13 0.77 5.4x10-9 EU, AA, AS [153, 218] 
rs7829816 
(C) 
[153] 
0.18  
LRRC18, 
WDFY4 10q11.23 1.24 7.2x10
-12 AS,EU [162, 168, 219, 220] 
rs1913517 
(A) 
[168] 
0.33 
rs877819 disrupts 
YY1 binding and 
decreases 
expression of 
WDFY4 
ARID5B 10q21.2 0.85 5.1x10-11 AS [168] 
rs4948496 
(C) 
[168] 
0.15  
CD44,PDHX 11p13 0.71 4.0x10-12 EU, AS, [169, 221] rs507230 0.44  
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AA (G) 
[169] 
PHRF1/IRF7/KI
AA1542 
 
11p15.5 
 
0.78 
 
3x10-10 
 
EU, AA 
 
[153, 154, 
162, 168] 
 
rs4963128 
(G) 
[168] 
 
0.07 
IRF7 Q412R 
increases IRE 
transcription 
DDX6, TREH 11q23.3 1.29 1x10-16 AS [222] 
rs4639966 
(G) 
[222] 
0.33  
ETS1 11q23.3 1.37 1.8x10-25 AS 
[168, 186, 
196, 198, 
219] 
rs6590330 
(A) 
[168] 
0.41  
GPR19, 
CDKN1B 
12p13.1-
p12 0.79 3.8x10
-17 AS [168] 
rs10845606 
(C) 
[168] 
0.27  
DRAM1 12q23.2 0.84 9.4x10-12 AS [168] 
rs4622329 
(A) 
[168] 
0.34  
SLC15A4 12q24.32 1.26 1.77x10-11 AS [168, 198] 
rs1385374 
(A) 
[168] 
0.25  
ELF1 13q13 1.26 1.5x10-8 AS [223]  
rs7329174 
(G) 
[223] 
0.28  
CSK 15q24.1 1.32 1.04x10-9 EU [224] 
rs34933034 
(A) 
[224] 
0.27  
ITGAM 16p11.2 1.62 1.61x10-23 EU, AS, HA 
[153, 154, 
162, 167, 
185, 215, 
219, 225-
227] 
rs9888739 
(T) 
[153] 
0.19 
ITGAM R77H 
compromises 
leukocyte adhesion 
and phagocytosis 
PRKCB 16p11.2 0.81 1.4x10-9 AS [228] 
rs16972959 
(A) 
[228] 
0.23  
CLEC16A 16p13.13 1.23 1.34x10-8 AS [229] 
rs12599402 
(A) 
[229] 
0.36  
IRF8 16q24.1 1.16 2.08x10-10 EU [164, 191] 
rs11644034 
(A) 
[191] 
0.17  
TYK2 19p13.2 1.20 3.88x10-8 EU [164, 185] 
rs280519 
(A) 
[164] 
0.47  
IKZF3 17q21 1.9 4.83×10−9 EU, AA, HA [191] 
rs8079075 
(G) 
[191] 
0.17  
ZPBP2 17q12 1.92 3.48×10−10  EU, AA [191] 
rs1453560 
(C) 
[191] 
0.06  
CD40 20q12-q13.2 0.63 2.0x10
-8 EU [230] 
rs4810485 
(T) 
[230] 
0.24  
UBE2L3/HIC2 22q11.21 0.78 1.48x10-16 EU, AS [153, 155, 168, 169] 
rs463426 
(G) 
[168] 
0.41  
TLR7 Xp22.3 0.60 6.5x10-10 AS [231-233] 
rs3853839 
(G) 
[231] 
0.19  
IRAK1/MECP2 Xq28 1.39 6.65x10-11 EU, AS, HA 
[154, 162, 
167, 234, 
235] 
rs1734787 
(C) 
[235] 
0.17  
aP < 5x10 8. bGenetic variants at 36 loci covering more than 50 genes have an established role in the etiology of 
lupus through association studies, replication in populations of diverse ancestry, and family studies. Some of the 
associated loci, such as 1q21 and Xq37, contain multiple genes. Until follow-up studies demonstrate or exclude the 
possibility of independent effects, all of the genes in the associated regions will remain candidate lupus genes. For 
HLA and complement, there are many different independent effects, which for simplicity, are summarized in a single 
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row. Variants in CFHR3/CFHR1, NMNAT2, ICA1, IKBKB, and SCUBE14 have P values approaching genome-wide 
significance (5x10 8 < P < 10 7) and are the focus of current replication studies. Population ancestry: EU, European; 
AA, African; AS, Asian; HA, Hispanic American. FCGR, Low-affinity Ig- FcR; NCF2, neutrophil cytosolic factor 2; 
CRP, C-reactive protein; TNFSF, TNF superfamily5  
 
To date, consensus surrounding the etiology and pathogenesis of lupus remains 
elusive. There is great potential in utilizing genetic studies to highlight signaling 
pathways that likely contribute to lupus pathogenesis. Genetic association data inform 
hypothesis-driven questions for functional biologists to elucidate underlying disease 
mechanisms.  
In this review we present the many genetic regions now identified as associated 
with lupus. We then discuss how the putatively responsible genes are often co-
expressed and cooperate in shared signaling pathways. Particular attention is focused 
on the convergence of lupus-associated variants in the B cell antigen-receptor (BCR) 
signaling pathway, as well costimulatory signaling pathways such as CD40, which 
synergizes with the BCR.  The enrichment of genes in these pathways provides insight 
into SLE pathogenesis and offers potential targets for future therapeutic strategies. 
 
Genetic associations with SLE 
Over the past two decades, lupus genetic studies have transitioned from 
identifying linkage effects using variable number tandem repeats in less common 
multiplex families, to the statistical association of alleles defined by single nucleotide 
polymorphisms (SNPs). The standard study design for association studies compares 
allele frequency of SNPs (or other variant markers) in cases and controls. These studies 
can be performed as candidate hypothesis-driven studies on one SNP or a handful of 
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SNPs in one gene. Alternatively, in hypothesis-generating genome-wide association 
studies, the assessment of millions of human SNPs facilitates the discovery of 
statistically associated genetic variants that serve as markers for the variants that are 
causal. Presently, deep sequencing studies are underway which allow the exploration of 
the entire variant genotypic complement of an individual. The incredible technical 
revolution of the past seven years, analogous to switching from horseback to a modern 
sports car seemingly overnight, fundamentally changes the conceptual character of the 
genetic approach. Contemplating a complete identification of the major genetic 
associations and their interactions is daunting; however, given the current trajectory of 
innovation these types of studies might well be possible within the foreseeable future. 
For lupus, fewer than 5% of the over 150 peer-reviewed and published 
associations are confirmed in the GWA era of genetic studies [236]. As the genotyping 
technology has become more sophisticated, the weak performance of the previous 
candidate gene and linkage eras became obvious for many disease related phenotypes 
[237, 238]; however, those genes that have been replicated such as IRF5 and STAT4 
have modest effects and should not be discounted. In the spirit of a reemphasis on the 
scientific method and the development of more rigorous statistical criteria before an 
association would be accepted as probably present, Pe’er et al. developed a genome-
wide criteria for significance in order to diminish the consequences of over-testing the 
data. They reasoned that the genome contains about 1 million independent elements, 
given the linkage disequilibrium present [239]. Therefore, the threshold for having a one 
in twenty chance of a false positive result (alpha error of 0.05) should be a probability of 
about 5x10-8 [239]. The problem is that this level of rigor requires large collections of 
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cases and controls to achieve adequate power with moderate expectations for effect 
size. Even then, the case-control design only has adequate power with a limited set of 
mechanisms of inheritance [240]. In fact, statistical power is very poor to detect 
recessive and epistatic effects, despite their presumed role in lupus etiology. The 
sample sizes required for most alleles operating through these mechanisms of 
inheritance are far beyond our current capacity. Notwithstanding the challenges, the 
application of these rules has allowed for the identification of more than 50 statistically 
convincing and replicated associations for the development of lupus (Table 4). 
Once an association is established, fine mapping studies are initiated with the 
aim of identifying genetic variants that are biologically responsible for the genetic 
association. Fine mapping studies are usually done by designing genotyping arrays that 
use the same chemistry as the GWAS arrays to genotype as many SNPs as possible 
around the detected lupus-associated variant. Many such array-based fine mapping 
studies limit the location of the causal variant to small physical regions of DNA. The 
Large Lupus Association Studies (LLAS-1 and LLAS-2), encompassing 20,000 - 30,000 
fine mapping markers and up to 18,000 subjects, have been effective for fine mapping 
identified loci (described in [143, 189, 241]). Subsequent studies currently underway 
with the 125,000 useful fine mapping markers on the ImmunoChip are expanding our 
ability to rapidly fine map associated regions, as has been recently accomplished for 
Celiac’s disease [242]. Another, more recent, approach is to obtain deep DNA 
sequence of physical regions around the associated variants in a sample of subjects in 
order to provide a characterization of the variation differences between the risk and non-
risk haplotypes. 
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Fine mapping studies of the strongest associations have revealed that identifying 
the causal variant is a non-trivial process for many genes. In fact, amino acid changing 
SNPs associated with lupus have only been identified and subsequently became 
candidate causal variants in 8 out of the 50 associated loci (Table 4). The linkage 
disequilibrium within associated regions results in many variants demonstrating 
statistical associations at a single locus. The evolutionarily diverse and four-fold longer 
population history of African ancestry makes possible important insights into variant 
identification that would not otherwise be possible from physical mapping experiments 
in Europeans; however, even when the genetic effect is localized to a few hundred 
bases, the functionality of the variant is not always directly apparent. While coding 
variants such as non-sense and mis-sense SNPs are easily annotated, variants that 
affect transcription factor binding sites, microRNA regulatory sites, RNA stability, or 
epigenetic regulation of a locus are more difficult to annotate given the current level of 
understanding. 
Oftentimes, finding the functional effect of an association through 
experimentation with genotyped samples can inform the analytical determination of the 
causal variant. For example, rs9888739 results in an arginine to histidine amino acid 
change at position 77 in ITGAM that putatively compromises leukocyte adhesion, which 
at present is accepted as the causal variant responsible for the genetic association in 
the genomic region around ITGAM [243]. In other cases, such as IRF5 and TNFAIP3, 
the association is due to the biological impact of multiple causal variants that affect the 
mRNA expression and stability [244, 245]. 
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Organizing the associations into testable pathways provides a framework from 
which to ask hypothesis-driven, biologically relevant questions. In lupus, several groups 
have suggested collections of associated genes that work together in a common 
pathway and activated by common stimuli. For example, of the ~50 genes now known 
from published and preliminary data to be convincingly associated with SLE, it is striking 
that 30 are directly or indirectly involved in the NFκB signal transduction pathway 
related to IRF5 and IRF7 (Figure 2). 
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Pathways in Lupus: Highlighting Genes in the B Cell Antigen Receptor-signaling 
Pathway 
Reducing the complexity of disease-associated genetic variants by identifying 
cell types and pathways is a well-established approach to dissect lupus pathogenesis. 
Categorizing statistically associated genetic variants may reveal and highlight potentially 
important disease mechanisms. For example, Hu et al. uses a novel statistical method 
to identify cell specific expression of lupus variants and finds a convincing enrichment of 
gene expression in transitional B cell genes [246]. Lupus susceptibility genes tend to 
cluster in the Toll-like receptor (TLR)/type 1 Interferon (IFN) pathway, immune-complex 
processing, immune signal transduction, and B cell receptor (BCR) signaling pathway 
[247]. 
Intuitively, one might assume that multiple variants within the same category 
would synergistically increase risk of disease. Geneticists use complex statistical 
approaches to measure epistasis between variants in the same pathway. Despite 
studies including up to 15,000 subjects, the association results to date generally support 
additive relationships between lupus susceptibility genes instead of synergistic, 
multiplicative, or epistatic models [248]. In the context of current findings consistent with 
additive models of association, our current working hypothesis is that small changes to 
specific pathways permit the events that result in broken tolerance and overt 
autoimmunity. 
To underscore significant lupus-associated genetic variants in B cell signaling 
pathways, we highlight the presence of proteins with established lupus associations in 
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the BCR signaling pathway (Figure 3) and interconnected costimulatory pathways 
(Figure 4) with red shading in the figures and bold font in the text. 
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B cells in lupus 
Patients with lupus progressively accumulate a number of autoantibodies 
directed against self-antigens, in particular anti-nuclear proteins[249]. While it is not 
clearly understood what leads to this break in self-tolerance, autoantibody production 
precedes overt disease manifestations and clinical diagnosis [46]. Autoantibodies are 
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thought to mediate many of the clinical sequelae of lupus, both indirect and direct. 
Renal disease in lupus is primarily caused by immune complex deposition in the 
glomerulus, leading to fibrosis and loss of glomerular filtration capacity [250]. 
Autoimmune hemolytic anemia is thought to be a result of clonal autoantibodies to cell 
surface antigens. Some lupus patients develop anti-phospholipid syndrome in which 
antibodies against the phospholipid-beta-2 glycoprotein I complex are associated with 
thrombotic events, placental infarcts leading to miscarriage, and liver dysfunction [251]. 
Given the role of autoantibodies in SLE pathogenesis, B cells have long been thought to 
play a crucial role in mediating disease. 
 
Signaling through the B cell antigen receptor (BCR) 
The BCR-mediated signaling cascade is a highly complex series of inhibitory and 
activating interactions that occur in spatial and temporal patterns (reviewed in [252, 
253]). BCR-mediated signaling begins when antigen binds and cross-links the BCR. 
Src-family protein tyrosine kinases (PTKs), such as Lyn, phosphorylate 
immunoreceptor tyrosine-based activation motifs (ITAMs) on Igα and Igβ, which then 
serve as docking sites for cytosolic Src homology 2 (SH2)-domain-containing PTK 
spleen tyrosine kinase (Syk), resulting in phosphorylation of Syk (Figure 3). Upon 
activation, Syk is central to multiple downstream signaling events (PLCgamma2-
SLP65/BLNK complex), resulting ultimately in cytoskeletal rearrangement, gene-
expression regulation, and cell-fate decisions. As PTKs are central to positive BCR 
signaling, protein tyrosine phosphatases (PTPs), such as Lyp, encoded by PTPN22, 
play an opposing role and serve as a balance to maintain homeostasis. PTPs are 
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recruited to the BCR signaling complex through immunoreceptor tyrosine-based 
inhibitory motifs (ITIMs) on inhibitory co-receptors such as CD5 and CD22 (Figure 3). 
ITIMs are also targeted by Src-family PTKs, however, ITIM phosphorylation results in 
recruitment of SH2-domain containing PTPs, which counteract the kinase activity of 
PTKs. Another mechanism by which BCR signaling is negatively regulated is by 
activation of the low-affinity Fcγ receptors (FcγRs), specifically FcγRIIb. This receptor is 
unique among FcγRs in that it has an ITIM, and phosphorylation of this motif results in 
attenuation of BCR signaling (Figure 3). 
Stimulation of B cells on coreceptors such as CD40 or through TLR activation 
synergize with BCR signaling and lead to B cell proliferation (Figures 3 and 4), cytokine 
production, antibody secretion, and isotype switching, each of which play potential roles 
in SLE pathogenesis. Different combinations of costimulatory signals allow B cells to 
produce cytokines and antibody isotypes for a specific inflammatory response. Genetic 
variants in these costimulatory pathways subtly affect how B cells generate an immune 
response. These changes could prejudice B cell responsiveness toward inappropriate 
breaks in tolerance leading, in some cases, to lupus.  
One distinct feature of the BCR signaling pathway is that in addition to second 
messenger mediated signal transduction, the BCR-antigen complexes are physically 
internalized and trafficked through the endocytic pathway to the MHC class II-containing 
compartment (MIIC). Here antigen is digested and loaded onto MHCII molecules prior to 
surface expression [254].  
 
BCR signaling in B cell selection 
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The mechanisms that allow auto-reactive B cells to escape negative selection 
and become antibody-secreting plasma cells in the periphery are poorly understood. It 
is clear that tolerance is broken in these auto-reactive B cells and that immune 
dysregulation is central to the etiology of lupus. Currently, we do not have clear 
mechanistic insight into how genetic and environmental factors sometimes result in the 
loss of immunological tolerance of self. B cell selection occurs in two general steps. 
Early selection prior to development into mature B cells, and later a second selection 
step occurs as mature B cells circulate in the periphery. Early B cell selection consists 
of two checkpoints. First, immature B cells in the bone marrow (BM) can undergo three 
distinct fate decisions based on binding affinity to self-antigen; high-affinity binding 
results in deletion, moderate-affinity binding leads to receptor editing via heavy and light 
chain gene rearrangement while low-affinity binding leads to anergy. The second 
checkpoint is less well understood, but is believed to occur as newly emerged 
transitional B cells circulate in the periphery prior to maturation. This is supported by the 
decreased numbers of autoreactive clones in the mature B cell pool when compared to 
the number of autoreactive clones in the pool of new-emigrant B cells, suggesting that 
some deletion of auto-reactive B cells has occurred in transit. Many suspect that this 
may result from a new-emigrant B cell’s encounter with autoantigen leading to 
subsequent negative selection [255]. 
 
Specific genes with a potential role in B cell signaling and survival 
 
LYN 
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LYN encodes a Src-family PTK that acts early in the B cell signaling pathway 
(Figure 3). Polymorphisms within LYN are associated with lupus in European-American 
women and the risk allele is the major allele [142, 256]. The specific genetic variant 
responsible for the lupus association with LYN is unknown though Lyn expression is 
decreased in B cells isolated from lupus patients. The decrease in expression also 
correlates with exclusion of Lyn from the lipid raft fraction in B cell digests [257, 258]. 
Lyn is one of the central mediators of signaling in B cells as it phosphorylates both 
ITAMs and ITIMs (Figure 3). 
Early results with LYN-/- mice revealed a lupus-like phenotype that suggested a 
role for Lyn in lupus pathogenesis. LYN-/- mice have decreased B cells in the periphery 
that display decreased proliferation and diminished phosphorylation of CD22 and 
FcγRIIb in response to anti-IgM stimulation [259]. Autoantibody levels are increased in 
LYN-/- animals, as is total IgM in the serum, which corresponds with an increase in the 
IgM+ B cell fraction [260]. While Lyn can phosphorylate both ITAMs and ITIMs of cell 
surface receptor complexes, its role in activating positive signaling pathways 
downstream of the BCR is redundant with Blk and Fyn [261]. Importantly, Lyn has a 
unique role in mediating negative signaling by phosphorylation of ITIMs in CD22 and 
FcγRIIb [262, 263]. In an effort to understand the mechanism of the B cell depletion in 
LYN-/- mice, Gross et al. generated mixed bone-marrow chimeras to define the 
competitive advantage or disadvantage of Lyn deficiency in B cells. The loss of LYN-/- B 
cells is a B cell intrinsic defect, as LYN-/- follicular B cells were reduced compared to 
wild type in mixed bone marrow chimeras. Mechanistically, this B cell contraction 
correlates with increased expression of the pro-apoptotic molecule Bim [264]. 
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As Lyn can act as both a positive and negative regulator, LYN-/- mice are used to 
investigate the balance between positive and negative signaling in peripheral B cells. 
Newly arrived splenic transitional (T1) B cells are progressively less sensitive to BCR-
induced signaling as they mature to follicular B cells. This is demonstrated by increased 
Ca2+ flux and second messenger phosphorylation in T1 B cells compared to follicular B 
cells following IgM stimulation. The increased signaling is most likely due to the 
upregulation of the CD22-SHP-1-Lyn regulatory axis, which is an important source of 
negative signaling (CD22 is increased in murine follicular B cells compared to T1 B 
cells). T1 B cells from Lyn-deficient mice show no change in BCR induced signaling 
compared to wild type, while Lyn-deficient follicular B cells are much more active than 
wild type cells [265]. These results further suggest a role of Lyn in maintaining negative 
signaling in B cells, particularly follicular B cells. While these results highlight a role for 
Lyn in the suppression of follicular B cell activation, loss of LYN does not affect 
tolerance during B cell maturation as LYN-/-IgHEL mice have no defect in negative 
selection [266]. These data identify Lyn as a key mediator of the FcγRIIb and CD22 
negative signaling pathways, which appear to be more important in mature B cells 
compared to early transitional cells, where stimulatory signals predominate, promoting 
negative selection. The increase in positive signaling observed in LYN-/- B cells may be 
enough to increase negative selection in early transitional B cells, leading to the 
decreased pool of transitional B cells in LYN-/- mice. The explanation for the emergence 
of autoreactive B cells and autoantibodies is not as clear given the decrease in B cells. 
Increased BCR signaling as a result of the decreased negative signaling in mature B 
cells due to Lyn deficiency is one explanation, but it may also be a product of the effect 
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of Lyn deficiency in myeloid cells that increases the inflammatory tendency of the 
cellular milieu [267]. LYN-/-MyD88-/- mice do not produce autoantibodies [268] due to the 
suppression of plasma cell differentiation. The development of autoimmunity in LYN-/- 
animals most likely arises as a result of the combination of the increased sensitivity of 
mature B cells to positive signaling pathways and the concurrent increase in 
inflammation mediated by LYN-/- myeloid cells and TLR-dependent stimulation.  
• Lyn is a Src-family PTK that can phosphorylate both ITAMs and ITIMs 
(Figure 3) 
• Lyn-mediated phosphorylation of ITIMs is crucial to dampen activation of 
follicular B cells in mice 
• Decreased levels of Lyn are associated with lupus 
• The major allele in the population is the risk variant for LYN 
 
BLK 
Blk is a Src-family PTK expressed predominately in B cells [269]. The genetic 
association between BLK and lupus in individuals of European descent was first 
identified at a SNP ~7kb upstream of BLK and confirmed in subsequent studies [142, 
270]. BLK expression is genotypic with people who carry two copies of the risk allele 
expressing more Blk than people carrying one copy or two copies of the protective 
allele [270]. The association of BLK with lupus has been replicated in Japanese [271] 
and Chinese [270] populations. 
BLK interacts with BANK1 genetically (with epistasis between the risk variants 
despite no increased lupus risk) and physically (by co-localizing) (Figure 3) [272]. Co-
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immunoprecipitation studies demonstrated a basal interaction between Blk and BANK1 
that was enhanced by IgM stimulation. Additionally, the expression of BANK1 appears 
to alter Blk localization, with Blk localizing to cytoplasmic compartments instead of the 
plasma membrane in the presence of BANK1 [272].  
BLK-/- deficient mice have no observable immune phenotype [273]; however, 
because Blk is functionally redundant with Lyn and Fyn, this is not surprising [261]. 
While Blk does not apparently have a unique role in mice, decreases in Blk expression 
may still have a significant impact on human disease, as is seen with another PTK 
family gene product, Bruton’s tyrosine kinase (Btk). Mutations in Btk in humans results 
in X-linked agammaglobulinemia, which can result in a complete lack of B cells. The 
phenotype in BTK-/- mice is not as severe, suggesting significant differences between 
PTK signaling pathways in humans and mice [274]. 
• Blk is a PTK that can bind both ITAMs and BANK1 (Figure 3) 
• A polymorphism in BLK associated with lupus is also associated with 
decreased expression of Blk 
  
BANK1 
B-cell scaffold protein with ankyrin repeats 1 (BANK1) is a B cell scaffold protein that 
binds both the Src family PTK Lyn and the inositol 1,4,5-triphosphate receptor (IP3R) in 
distinct regions. Upon BCR stimulation, BANK1 is phosphorylated, favoring Lyn binding 
(Figure 3). Dual binding of Lyn and IP3R permits Lyn-mediated phosphorylation of IP3R, 
leading to Ca2+ mobilization from intracellular ER stores [275]. BANK-/- mice have been 
developed and found to have slightly increased numbers of mature B cells, increased 
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serum IgG2a and increased formation of germinal centers. Following CD40 stimulation, 
B cells from BANK1-deficient mice demonstrate enhanced proliferation and survival. 
BANK1-/-,CD40-/- mice rescue the phenotype. The increased survival and proliferation of 
B cells depends on CD40 activation of TRAF6 which is essential for Akt ubiutination, 
membrane recruitment , and phosphorylation.  Further mechanistic characterization of 
the BANK1-/-CD40-/- mice suggest that BANK1 acts as a negative regulator of CD40-
induced survival signals via the suppression of Akt [276]. The connection between the 
role of BANK1 in Lyn-mediated signaling and the role of BANK1 in CD40 mediated 
signaling within B cells remains to be explored, as does the possibility that BANK1 has 
actions that influence the BCR and CD40 pathways distinctly at different times over the 
life of a B cell. Future studies will also need to address the role of BANK1 in B cell 
signaling pathways apart from CD40 and Lyn. Two major isoforms are identified for 
BANK1: one full-length isoform and a truncated isoform lacking all of exon 2, named Δ2 
[277]. 
Kozyrev et al. identified three potential functional variants associated with lupus 
in Europeans, a finding which we subsequently replicated [277, 278]. rs17266594 is in a 
putative branch point site in intron 1, but was later shown not to be essential for splicing 
[279]. rs10516487 codes for an R61H variant in exon 2, and rs3733197 which codes a 
A383T variant in exon 8 [277]. The non-synonymous SNP rs10516487 is located in the 
second exon and is in high linkage disequilibrium with rs17266594 (r2=0.90). The 
protective minor allele A results in a coding change from Arg to His at position 61, 
resulting in the creation of a recognition site for the splicing enhancing factor SRp40. 
Presence of this binding site appears to inhibit splicing of exon 2. In addition, the A 
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allele was associated with lower levels of BANK1 expression at both the message and 
protein level. The exact relationship between the R61H variant and the Δ2 isoform are 
not firmly defined, but the Δ2 isoform lacks the IP3R binding domain and when present 
either alone or with full-length BANK1, is diffusely distributed in the cytoplasm instead 
of clustered into punctae as is the full length isoform when present alone. Thus, 
heterologous dimer formation may be an important mechanism of BANK1 regulation, 
determining cellular location and access to interacting proteins [279]. While the 
identification of these potential causal variants is promising, the exact relationship 
between SLE-associated variants in BANK1 and disease pathogenesis remains 
unclear. Further studies focused on understanding the effect of these functional variants 
on the CD40 signaling pathway will help clarify the role of BANK1 in SLE pathogenesis.  
• BANK1 is a scaffold protein that can bind PTKs and IP3R (Figure 3) 
• Multiple functional polymorphisms in BANK1 are associated with lupus, 
although the casual variants are not yet identified 
• B cells from BANK1-deficient mice proliferate in a CD40-dependent manner  
 
PTPN22 
PTPN22 encodes Lyp, a PTP found in lymphocytes [280]. A variant of PTPN22 
(1858C/T) is associated with multiple autoimmune diseases, including RA [281], SLE 
[282], T1D [283], Graves disease [284] and myasthenia gravis [285]. The association 
between PTPN22 and SLE is well established in multiple ancestries [286] and seems to 
be entirely explained by the 1858C/T polymorphism. This genetic variant results in the 
amino acid substitution R620W, producing Lyp 620W. 
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Lyp interacts with Csk, a PTK family member, to regulate phosphorylation of Src 
family kinases downstream of cell-surface receptors including the TCR, BCR and CD40 
(Figure 3). Early studies demonstrated that the R620W substitution disrupts Lyp binding 
to Csk [283]. The Lyp 620W variant has been studied in lymphocytes isolated from 
patients with lupus, T1D, and myasthenia gravis. The functional consequences of the 
Lyp 620W variant in autoimmune disease were first reported in T cells isolated from 
T1D patients [283, 287]. In these cells, TCR engagement resulted in decreased 
phosphorylation of downstream targets, decreased Ca+2 flux, and decreased IL-2 
production [287]. Given these findings, the Lyp R620W mutation was proposed to be a 
gain-of-function mutation, resulting in decreased signaling through the TCR in cells 
carrying the disease-associated phenotype [287]. Subsequent work in isolated T cells 
appears to have confirmed these findings [288, 289]. However, other groups have 
reported the opposite phenotype in both peripheral blood mononuclear cells (PBMCs) 
and T cell lines simultaneously transfected with both Lyp and Csk [222, 290]. While T 
cells isolated from individuals carrying the Lyp R620W mutation may represent a more 
physiological assessment than overexpression of Lyp in vitro, these differences remain 
to be reconciled. 
Current efforts to resolve these differences have focused on the mouse 
homologue of Lyp: PEP. Zikherman et al. crossed PEP-/- mice with CD45w/w mice, which 
contain a point mutation in the CD45 juxtamembrane wedge domain (E613R), in which 
hyperactive CD45 signaling leads to B cell-driven autoimmunity [222]. The PEP-/-
CD45w/w animals develop a lupus-like disease, similar to CD45w/w mice, but with 
increased anti-double stranded DNA IgG. B cells from PEP-/-CD45w/w mice are similar to 
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those from CD45w/w mice. While attempts to understand the effect of PEP deficiency on 
the development of autoimmunity have not been impressive, to date, other mouse 
models have been developed to specifically test the hypothesis that the Lyp 620W 
mutation will lead to increased autoimmunity. To test this hypothesis, mice expressing a 
PEP variant similar to Lyp 620W, PEP 619W, were developed. Expression of the Lyp 
620W/ PEP 619W variant results in lower Lyp/PEP protein expression due to increased 
calpain- and proteasome-mediated cleavage and degradation, causing an increased 
activation of lymphocytes in these mice [291]. 
  The Bruckner lab has produced numerous studies over the last few years 
examining the phenotype of B cells isolated from human subjects carrying the 1858C/T 
PTPN22 polymorphism. Individuals carrying at least one copy of the risk allele have 
reduced memory B cells in the periphery [289], along with increased transitional and 
anergic naïve B cells [292]. Strikingly, autoreactive B cell clones are more frequent 
within these pools of transitional and mature naïve B cells. These B cells are also more 
sensitive to CD40L and IgM crosslinking by measure of surface activation markers 
[293]. In contrast to what occurs in the transitional and anergic naïve B cell pools, the 
memory B cell population of individuals carrying the lupus-risk allele demonstrate a 
decrease in Ca2+ mobilization and proliferation following treatment with anti-IgM in vitro. 
In addition, stimulation of these memory B cells results in a reduction in phosphorylation 
of downstream targets, including Syk and PLCy. The genotypic attenuation in these 
signaling pathways can be restored following treatment with the Lyp inhibitor I-C11 
[294]. These studies suggest that PTPN22 plays a crucial part in early B cell tolerance 
checkpoints, with Lyp 620W permitting progression of autoreactive clones to the 
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periphery. These results also highlight the B cell-intrinsic effects of Lyp; however, 
PTPN22 mutations in T cells may still be important in the modulation of B cell activation. 
Decreased signaling through the TCR could also affect Treg function, thereby allowing 
autoreactive B cells that escaped to the periphery as the result of PTPN22 mutations 
during selection to be activated and drive SLE pathogenesis.  
If Lyp 620W does represent a gain-of-function mutation, then one explanation for 
the phenotype observed in individuals with the 1858C/T polymorphism would be that a 
hyperfunctional Lyp restricts activation of key second messengers, as evidenced by 
decreased phosphorylation in cells with Lyp 620W, raising the threshold for cellular 
activation. A higher activation threshold in transitional and naïve B cells could allow 
persistence of B cell clones that would otherwise be deleted through high-affinity 
binding. This is reflected in the increase of autoreactive cells in the pool of transitional B 
cells and importantly, may be a key event in the breakdown of tolerance and 
progression towards autoimmunity as the increase in autoreactive clones mirrors what 
occurs in Type 1 Diabetes (T1D) [293].  
In an additional layer of complexity, gene expression analysis identifies IRF5 as 
one of the genes upregulated in B cells from 1858C/T individuals [293]. IRF5 is well 
established as being an important SLE risk gene. Increased IRF5 expression is 
associated with Type I IFN production [295], suggesting that the PTPN22 risk allele may 
also promote cellular activation in the periphery. This represents a further mechanism 
by which alterations in which PTPN22 polymorphisms promote autoimmunity.  
• PTPN22 encodes Lyp, a PTP important for negative regulation of B cell 
signaling (Figure 3) 
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• A PTPN22 risk allele, the Lyp 620W putative casual variant, is associated 
with numerous humoral autoimmune diseases 
• Lyp 620W is associated with increased activation of transitional and 
follicular B cells and decreased activation of memory B cells 
 
TNFAIP3 
Tumor necrosis factor alpha inducible protein 3 (TNFAIP3), encoding the 
ubiquitin-modifying protein A20, was first identified as a risk gene in RA [296, 297] and 
has since been associated with multiple autoimmune diseases, including lupus [298, 
299], Celiac disease [300], Crohn’s disease [301], T1D [302] and psoriasis [303]. 
Recently, a TT>A deletion polymorphism was proposed to be the causal variant 
responsible for disease association in lupus. This deletion is downstream of the 
TNFAIP3 gene in an apparent regulatory region. Oligonucleotides with the deletion 
display decreased binding of the NFκB subunits p50, p65 and cREL and reduced 
overall TNFAIP3 mRNA expression according to the number of risk chromosomes (0, 1 
or 2) present in the sample [304]. These results suggest that decreased A20 levels are 
a risk factor for lupus. 
A20 is an ubiquitin-editing enzyme induced by CD40 activation and signaling by 
proinflammatory cytokines such as TNFα and IL-1β.  A20 modulates cell signaling by 
both removing K63-linked ubiquitin chains from signaling intermediates and by adding 
K48-linked ubiquitin chains [305]. In general, the addition of K63-linked ubiquitin chains 
is activating while K43-linked polyubiquitination targets proteins for proteosomal 
degradation. The main byproduct of ubiquitin editing events is to limit NFκB activation, 
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aiding in the maintenance of immune homeostasis (Figure 4) [306]. Recent evidence 
suggests that inhibition of IKKβ phosphorylation by A20 may be independent of A20 
enzymatic activity, though still dependent upon ubiquitin binding [307]. A20 deficient 
mice develop massive systemic inflammation resulting in cachexia and multi-organ 
failure leading to early death mediated by failure to restrict NFκB signaling [308]. 
Crossing A20 -/- mice with MyD88-/- mice rescues the phenotype by restricting 
ubiquitination of TRAF6 [309], suggesting that A20 plays a prominent role in dampening 
homeostatic MyD88-mediated inflammatory signaling (for a recent review see [310]). 
Mice with TNFAIP3 conditionally deleted in B cells (CD19+) were recently 
developed by two separate groups [311, 312]. Both report significant changes in B cell 
populations, including increased plasma cells in older mice, immune complex deposition 
in the kidney and increased IL-6 production. Tavares et al. reports significant 
autoantibody production [312], but it is not clear if these are IgM or IgG autoantibodies. 
Since some IgM autoantibodies may be protective [313], the implications of this finding 
are not immediately obvious. The TNFAIP3-deficient mice studied by Chu et al. had 
high levels of IgM in the sera and class-switched anti-cardiolipin IgG in older mice [311].  
Furthermore, both groups also report changes relevant to splenic B cells in the B 
cell conditional TNFAIP3-/- mice. Chu et al. finds that marginal zone B (CD1d+) cells are 
located in the follicle of the spleen, with little to no B cells in the marginal zone. In 
addition, they demonstrate that splenic B cells fail to differentiate into Blimp1+ 
plasmablasts following LPS stimulation in vitro [311]. Tavares et al. also identify 
alterations in splenic B cells, noting an increase in germinal center B cells [312]. 
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To test the hypothesis that A20 plays a role in Fas-mediated programed cell 
death in germinal center negative selection [314], programed cell death was induced by 
agonist anti-CD95 stimulation in vitro. Indeed, A20 deficient cells are resistant to Fas-
mediated programmed cell death. The resistance to Fas-induced apoptosis correlates 
with an increase in the anti-apoptotic molecule Bcl-x, a molecule that is normally 
suppressed by the NFκB pathway [311]. Notably, both groups observe a dose effect in 
response to A20 deficiency in B cells, consistent with a pathogenic role for alleles 
producing less active A20 leading to B cell hyperreactivity in human autoimmunity.  
Taken together, A20 is potentially critical to the homeostatic dampening of NFκB 
signals and that decreased protein expression is sufficient to tip B cells toward an 
autoimmune phenotype and loss of tolerance. While the exact mechanism remains to 
be identified, the results from conditional knockout mice suggest that decreased 
expression of A20 may result in the production of B cells resistant to negative selection 
in the spleen. In addition, increased IL-6 produced by these animals may also promote 
the survival of autoreactive plasma cells and T cell mediated pathogenesis. Obviously 
much work remains to connect these murine phenotypes with the genetic associations 
reported in human SLE. However, given the findings that SLE-associated genotypes 
correlate with lower A20 expression and that decreased A20 in murine B cells results in 
resistance to negative selection, in vivo studies aimed at tying together these 
observations will be an exciting next step in using B cell signaling pathways to 
understand statistical genetic associations. 
• TNFAIP3 encodes A20, a ubiquitin editing enzyme that can both add and 
remove ubiquitin chains from target molecules (Figure 4) 
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• A20 can regulate inflammation via attenuation of MyD88-dependent NFκB 
signaling in mice 
• A lupus-associated proposed causal variant in TNFAIP3 is statistically 
associated with lower expression of A20 
 
TNIP1 
TNIP1 encodes an ubiquitin-binding adapter protein A20-binding inhibitor of 
NFkB, ABIN-1, that binds and cooperates with TNFAIP3 in suppressing NFκB (Figure 
4). Also known as NAF1, polymorphisms in TNIP1 are associated with lupus in both 
European derived and Asian populations [143, 315]. TNIP1 can be differentially spliced 
into at least 11 different isoforms [316] each of which suppress NFκB activation with 
different levels of inhibition. Whether the lupus-associated risk variant of TNIP1 alter 
splicing or NFκB activation is not yet known. 
Deubiquitination and degradation of ubiquitinated signaling proteins are key 
mechanisms by which ABIN-1 cooperates with A20 to limit T lymphocyte receptor 
(TCR) signaling as part of a negative feedback loop. Coexpression of ABIN-1 together 
with A20 in HEK293 cells contributes to the negative regulatory function of A20 in TNF-
α–mediated NFκB activation [317]. Mechanistically, ABIN-1 interacts with A20 
independent of the ubiquitin-binding domain to mediate the NFκB inhibitory function of 
A20 [318].  
ABIN-1 also binds the MAP kinase ERK2 and causes retention of ERK2 in the 
cytoplasm, leading to reduced signaling [319]. siRNA mediated knockdown of ABIN-1  
results in increased IFN-β production following either viral infection or polyI:C 
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administration in vivo, which is dependent upon the ubiquitin-binding domain of ABIN-1, 
suggesting that ABIN-1 suppresses viral-induced IFNβ production [320]. Interaction 
between ABIN-1 and the toll-like receptor (TLR) pathways is further supported by the 
finding that ABIN-1 recognizes K63-linked polyubiquitin chains on NEMO. NEMO is the 
IKKγ subunit of the NFκB signaling complex. NEMO activation is necessary for the 
nuclear translocation of NFκB. While K48-linked polyubiquitination of NEMO targets it 
for subsequent proteasomal degradation K63-linked polyubiquitination of NEMO 
regultates its activity, but not half-life [321].  
TNIP1-deficient mice develop progressive, lupus-like inflammatory disease. The 
development of the lupus-like disease is dependent on leukocytes, as bone marrow 
transplantation of wild type mice with TNIP1-/- bone marrow is sufficient to initiate 
autoimmunity. ABIN-1 is recruited to the MyD88 signaling complex and controls TLR-
mediated activation of the major isoform of “CCAAT enhancer-binding protein b” 
(C/EBPb) which is known as LAP (liver-enriched activator protein) which has been 
shown to mediate TLR-dependent inflammatory cytokine production [322]. In fact, mice 
carrying a mutant TNIP1 that cannot bind ubiquitin also display an autoimmune 
phenotype. Ubiquitin binding is rescued by crossing the mice onto a MyD88-/- 
background [323]. Stimulation with TLR ligands, BCR crosslinking, or a CD40 agonist all 
caused enhanced phosphorylation and activation of the NFκB pathway in ABIN-1 
mutant mice compared to wildytpe mice [323]. These murine studies lead us to 
conclude that ABIN-1 cooperates with A20 in BCR signaling through interaction with the 
signaling pathway components downstream of both CD40 and the BCR. 
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We recently reported a potential genetic association between SLE and another 
protein involved in ubiquitination, TRAF6 [324]. TRAF6 is an E3 ubiquitin ligase that has 
been identified as being important in numerous immune functions by activating NFκB 
following stimulation of BAFFR, TNF receptors, TLRs and CD40 [325, 326]. While the 
results of these first association studies will need to be replicated in many more people 
to confirm this association, they are consistent with the reported association of TRAF6 
with rheumatoid arthritis, also a humoral autoimmune disease. These results emphasize 
the importance of ubiquitin-mediated modulation of cellular activation pathways. The 
associations between these genes and lupus suggest a fruitful area of research in 
working to elucidate the mechanisms by which disruptions in ubiquitination can facilitate 
the onset of autoimmunity (See Figure 4). 
• TNIP1 encodes a ubiquitin-binding adapter protein, ABIN-1, that binds both 
ubiquitin and A20 (Figure 4) 
• Several genes involved in the ubiquitin regulatory pathway (e.g., TNIP1 and 
TNFAIP3) are associated with lupus highlighting the importance of this 
pathway in the development of autoimmunity  
• ABIN-1 has anti-inflammatory activities that are both dependent and 
independent of ABIN-1 ubiquitin binding in mice 
• ABIN-1 attenuates MyD88/NFκB inflammation in mice in part by targeting 
NEMO for proteasomal degradation; furthermore, ABIN-1 acts 
independently of MyD88 downstream of BCR and CD40 signaling. 
  
Concluding Remarks 
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B cells are gaining newfound respect, now being appreciated as more than 
immunoglobulin factories. Indeed, the genetic evidence supplements other data 
supporting their critical role. Early case reports for small clinical studies using B cell 
depletion therapies showed promise that these strategies would prove to be highly 
effective in treating lupus [91, 327, 328]. Unfortunately, larger random control studies 
did not replicate these findings [95, 329]. Similarly, the first drug approved for lupus in 
50 years, belimumab, targets BAFF, a cytokine essential for B-cell survival and 
proliferation, and has shown modest benefit in clinical trials [330]. These results 
underscore the fact that there are other factors that contribute to inflammation and SLE 
pathogenesis. These targeted approaches will most likely be more effective in a subset 
of SLE patients. B cell-related genetic risk variants may one day be used in more 
sophisticated and successful clinical approaches, including identifying which patients 
will be most likely to respond to specific therapies. 
We are early in the effort to understand how sequence changes to specific genes 
can affect lupus risk. As each of the lupus-associations is progressively evaluated, 
many complex, interconnected and sometimes contradictory stories are likely to 
emerge. The controversies and apparent contradictions in studies of PTPN22 and LYN 
may foreshadow potential contradictions as we learn more about less studied 
associations such as BANK1. In fact, a decade ago PTPN22 was thought to have a 
mechanism that operated through T cells. Now the evidence is just as strong that lupus 
risk related to PTPN22 is operating through B cells. The history surrounding studies that 
ascribe molecular mechanisms to explain genetic effects gives us a glimpse at the 
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challenges of forming a reasonable conceptual framework to understand how risk of 
disease is generated. 
Epstein-Barr virus (EBV) may play a significant role in the etiology of lupus. 
Briefly, the very earliest autoantibodies to appear in pre-clinical lupus patients are cross-
reactive with EBV proteins, including EBNA-1, an EBV-encoded molecular mimic of 
SLE-associated autoantigens such as Sm and Ro [46, 331]. In addition, EBV 
seroconversion [332] and viral load are increased in lupus cases compared to controls 
[333]. Several of the BCR-associated lupus genes discussed in this review play a role in 
EBV replication and immune evasion. For example, LYN has been shown to be the 
preferred signaling protein for the major EBV latency protein latent membrane protein 
2A (LMP2A), which acts as a BCR functional mimic, permitting B cell survival and 
preventing apoptosis of EBV infected B cells at least in part by co-opting the B cell 
signaling apparatus, including lipid rafts [334]. A20 has also been shown to be important 
in EBV infection of B cells, as A20-mediated ubiquitination of IRF7 is stimulated by the 
EBV protein latent membrane protein 1 (LMP1) [335], which functions as a CD40 
functional mimic to stimulate B cells. A20 competes with the LMP1 complex in activation 
of the NFκB pathway, altering the ability of LMP1 to drive NFκB activation.	
The biological impact of lupus-associated genetic variants in genes known to be 
important for EBV infection such as LYN and A20 will be of special interest moving 
forward, as an individual’s immune response to EBV infection (and the immune 
dysregulation caused by EBV-encoded mimics of key B cell activators) may provide 
important insight into EBV-associated lupus pathogenesis. 
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This review focused on the signaling in B cells and the corresponding lupus risk 
genes (Figures 3 and 4). Other aspects of B cell signaling, including BCR internalization 
and delivery of antigen to the MIIC are also known to have major roles in regulating B 
cell responses [336]. Genes in these pathways remain likely candidates for lupus. Also, 
other lupus genes, such as STAT4 and IRF5, are important transcription factors that 
mediate the response of many different cells, including B cells, to inflammatory stimuli. 
Yet other genetic associations are in genes for which little is known. Further 
investigation might well reveal newly recognized proteins with critical B cell functions. 
As more sophisticated techniques become available, we may find that risk 
polymorphisms in separate pathways act in concert to facilitate cellular changes 
conducive to tolerance breakdown and autoimmunity. 
Indeed, all the known genes together only account for a minority of the genetic 
heritability, as has been discussed for complex genetic diseases in general [337]. 
Together, small changes in proteins caused by common genetic variants alter B cell 
behavior toward a breakdown in tolerance and autoimmunity. Even after each of the 
individual associations are mechanistically understood, the practice of identifying the 
etiological mediators of lupus in patients presenting in clinic will require a sophisticated 
understanding of the interactions of the proteins in molecular pathways, such as the 
BCR signaling cascade and the regulation of ubiquitin modification. By integrating 
genetic and biological data through multi-disciplinary studies, we will prime ourselves for 
success in the coming age of personalized genomic medicine. 
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Chapter 3: Approach to Data Processing and Statistical 
Analysis in Genetic Association Testing 
 
Introduction 
The problems of Big Data analysis are widespread across many industries, from 
science to advertising to market research. The field of genetics is currently experiencing 
a period of great discovery, powered in large part by the increased capacity to query the 
genome. With the advance in technology available to the genetic researcher and the 
subsequent massive increase in data, there has been a rapid development of new tools 
specifically tailored to address the analysis needs of the genetic research community. 
There exists now a plethora of very specific tools, each addressing specific data types 
or analysis strategies. Whether beginning with processing raw sequencing or SNP-chip 
data to performing advanced statistical analysis of multiple data sets using different 
statistical approaches, there are most likely multiple options available for each step. 
Many of these tools are developed by bioinformaticians and computer scientists with 
specific interests in genetic analysis and software development. The tools they produce 
are most often open source to the research community and are continually updated and 
supported by their original creators. 
While these programs can be quite powerful, they are often quite narrow in focus 
and complete analysis of any project requires utilizing multiple tools developed by a 
variety of labs. This creates a challenge to even an experienced bioinformatician as 
many of these programs were developed for different computer operating systems, have 
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sometimes little to no instructions on use and getting support from the developers can 
be problematic. For the genetic researcher without a background in computer science 
the learning curve can be prohibitively steep. The emergence of large software suites 
created by independent software development companies is an attempt to address 
these obstacles. They are designed to include many different types of analysis tools and 
are user friendly but come at a steep cost, with individual licenses running into the 
thousands of dollars a year. 
Another obstacle presented by the advent of large genetic data sets is the 
amount of computer resources needed to perform a given analysis often exceeds the 
resources of an individual workstation. In addition, some analysis jobs can take many 
hours to days to complete, making it impractical to run on an individual user’s machine. 
To overcome this limitation of processing power and time constraints, many institutions 
have developed large computational clusters consisting of hundreds of processing cores 
which can used to run analysis jobs. For example, the CCHMC computational cluster 
(bmi.cchmc.org/resources/clusters) has over 700 processing cores and runs under a 
Linux-based operating system. Users can access the cluster from both on and off-
campus IP address. Jobs can be submitted and queued until the computational 
resources requested are available on the cluster. An individual user can also submit 
multiple jobs simultaneously, greatly increasing efficiency. 
Given the specific needs of our lab to be able to analyze various types of genetic 
data reliable and consistently, with the need to consistently and rapidly repeat the 
analysis with new data sets as available, we developed a series of best practices to 
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ensure that we were consistent with the genetic analysis we performed on each data set 
and of equal importance, that even the newest member of the lab, with some initial 
introduction and previous moderate familiarity with computers would be able to produce 
reliable and repeatable data quickly. To facilitate reproducibility and ease of use, we 
also developed a series of Linux bash scripts, essentially short computer programs, 
which can be used to submit analysis jobs to the CCHMC computational cluster in a 
simple and repeatable manner. The data set types we chose to focus our initial effort on 
were large SNP genotype databases that are used in association studies. Some initial 
processing had already been performed, including base calling (identifying the exact 
DNA base at each given genotyped location) and population stratification (a method to 
identify hidden influences from ancestral background which may otherwise confound 
results). As such, the current methods concern analyses subsequent to this step. 
 
Methods 
The datasets we used were generated as part of the follow-up fine-mapping 
project Large Lupus Association Study 2 (LLAS2) [338] based on the results from our 
lupus GWAS [142]. The data contained genotype information at hundreds of thousands 
of bases across the genome for tens of thousands of individuals. Additionally, there was 
also collected at the time of participant recruitment clinical information on a variety of 
lupus-related phenotypes. 
 
Logistic Regression 
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The basic analysis upon which all subsequent tests are based consisted of 
logistic regression of the SNP genotypes- comparing cases and controls for increased 
occurrence of any given SNP in one group versus the other. This analysis was 
performed in PLINK (v1.07) [339]. We began with data cleaning steps, filtering out SNPs 
with more than 10% missing genotypes, then removing individuals missing more than 
10% genotype information, then removing SNPs with minor allele frequencies (MAFs) 
below 1% and finally, removing markers that deviate significantly from Hardy-Weinberg 
equilibrium. The admixture values for each individual estimating their ancestral origins 
were included as covariates in the analysis. The results from this test were used for 
most subsequent analysis and provide a broad picture of the overall association in the 
region. 
 
Bayesian analysis 
As a complementary test using a Bayesian statistical approach, and as a method 
of validation, we calculated the Bayes factor for each SNP using SNPTEST [340-342]. 
We then calculated the posterior probability for each SNP, which provides an estimate 
of the fraction of the total regional association accounted for by each individual SNP. 
This strategy has been described in ref [343] For this analysis we again controlled for 
population stratification by using the admixture values for each individual as coviariates 
in the analysis. 
 
Imputation 
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Following the initial logistic regression analysis, we then imputed the region 
against the 1000 Genomes Project composite imputation panel in IMPUTE2 [245, 340, 
344]. Imputation is used to fill in the missing genotypes at untyped SNPs from the 
original fine-mapping dataset. By leveraging the more complete regional structural 
information from the 1000 Genomes samples the complete genotype information for the 
common variants in the region can be accurately estimated for the individuals in our 
study. Imputed genotypes are required to meet or exceed a probability threshold of 0.5, 
and information measure of >0.4. Again highlighting a common difficulty in these 
analyses, the data format used in PLINK is incompatible with IMPUTE2, so there is a 
step of data conversion both before and after imputation. Following imputation, the data 
is again cleaned in PLINK using the same steps to ensure that no abnormalities were 
introduced during imputation. After cleaning, the dataset is ready for a logistic 
regression analysis using the same tests as before.  
 
Conditional analysis 
The results of an association test are useful in highlighting an area of the genome 
most likely to contain a variant responsible for the detected association. The challenge 
is that most often multiple variants are associated with the phenotype in question. 
Conditional analysis, specifically step-wise logistic regression, in which genotype 
information at specific variants is included in the logistic regression testing as a 
covariate can be useful in understanding the contribution of that variant to the overall 
signal at the locus. Conditional analysis is especially useful in identifying the number of 
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independent associations in the region. In a region with only one true association, even 
though there may be many highly associated variants across a large area of the 
genome, step-wise regression controlling for a single, highly associated variant, will 
account for most of the signal in the region, increasing the p values of all tested 
variants. When the reduction in signal is universal across all variants, and the individual 
p values are increased to be no longer significant, we can conclude that there is most 
likely only one source of association in the region. 
In other regions, there may be multiple causal variants underlying the association 
in the region. In this case, controlling for the genotype at a single variant will reduce the 
signal for a portion of the associated variants in the region, but not for others. Single 
variant conditioning can identify which variants are associated with each overall effect, 
then multiple variant testing can be used to determine which variants can adjust for the 
entire signal in the region. 
 
Haplotype estimation and testing 
Haplotypes are the specific alleles within a genetic region that are commonly 
inherited together. Haplotypes occur as a result of the linkage disequilibrium (LD) within 
a region. LD is a measure of the propensity of two alleles to be inherited together and is 
related closely to their genomic distance from one another. Variants that are closer 
together are less likely to be separated by crossover events. Two variants in high LD 
are more likely than two variants with low LD to be inherited together and be part of the 
same haplotype. Haplotype blocks can be constructed based on measuring the LD in 
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the region. The method we use was described by Gabriel et al [345] and constructs 
blocks based on 95% confidence bounds based on D prime (a measure of LD). A 
haplotype block is defined as 95% of the variants in the block are all in “strong LD” with 
one another. 
We estimate haplotype blocks using the Gabriel method in either PLINK or 
Haploview, the later having the advantage of displaying an LD plot where blocks and 
regional LD patterns can be visualized. Following haplotype block estimation, we again 
perform logistic regression association, testing each haplotype instead of each 
individual variant. 
 
Meta analysis 
Meta analysis in genetic association studies is often used in the traditional 
manner to combine results from different studies. A related, more specific use of meta 
analysis, is to combine results from separate ancestral populations. Transancestral 
analyses in genetic association studies are a powerful way to identify shared disease 
risk and common risk variants amongst different ancestries [346]. Evolutionarily older 
populations, such as those originating in Africa, have had more time for crossover 
events and genetic recombination to occur, resulting in smaller haplotype blocks. This is 
in contrast to younger populations, such as those in Europe, where less recombination 
has occurred and haplotype blocks are larger. As a result of this difference between 
ancestral groups, meta analysis can often identify shared risk variants between the 
ancestries, leveraging the advantage of larger blocks in a younger population which 
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allow broad identification of associated regions, with the advantage of the smaller blocks 
of an older population which allow for some narrowing down of the association. 
 
Data Visualization 
A key aspect of our analysis pathway is data visualization. Visual inspection of 
results can be used to guide the next steps analytically, including highlighting regions of 
the genome for further refinement. Major computational errors in analysis can also be 
quickly detected by viewing the results graphically. We utilized the statistical software 
package R for our graphical output. R is a robust, open-source statistical graphing 
software package developed around the R programing language. We developed a 
series of scripts we use to prepare our association data for publication ready plots. For 
Manhattan plots (Figure 5), we used the R package qqman. For our association plots, 
we used ggplot and 
developed custom 
functions based on 
code provided by C. 
Lessard as seen in ref 
[347]. We have 
focused on presenting 
the data in such a way 
as to highlight imputed 
vs. directly genotyped 
Figure 5: Manhattan plot of the P values obtained from the 
genome-wide association analysis. 
Data are from 736 subjects with EoE and 9,246 controls over 1,468,075 
genetic variants with MAFs greater than 1% in the subjects with EoE. The −
log10 value of each probability is shown as a function of genomic position 
on the autosomes. Genome-wide significance (red dashed line; P ≤ 5 × 10−
8) and suggestive significance (solid blue line;
P ≤ 1 × 10−7) are indicated.
!
!
 
!
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variants. The overall regional association is also highlighted as the LD between the top 
variant (or other select variants as needed) and the other variants in the locus (Figure 
6). The Bayes factors identify the 95% credible set. The results of this script can be 
seen in our published work (Figure 10). 
Figure 6: R script used to generate association plots. 
One example of an R script used to visualize the results of a fine-mapping analysis 
including imputation and LD results. The recombination rate for the region is included 
and genes are plotted using information in biomart, a public database. 
 
require(biomaRt) 
#read in map and results 
#This is the recombination map 
combined3<-read.table("genetic_map_chr3_combined_b37.txt",header=T) 
#These are the imputation results 
chr3<-read.table("EA_apr.assoc.logistic",header=T) 
#These are the results specific to LLAS2 
llas2<-read.table("EA_pxk_admix_ci.assoc.logistic",header=T) 
chr3Mb<-chr3$BP/1000000 
llas2names<-llas2$SNP 
combined3Mb<-combined3[,1]/1000000 
#These are for plotting LD, if it's in the file 
LD <- chr3$R2 
 
#subset the file based on LLAS2 SNPs 
sub<-chr3[chr3$SNP %in% llas2names,] 
subMb<-sub$BP/1000000 
 
#Get information for the SNP you'd like to highlight 
rs76<-chr3[grep("rs4681677",chr3$SNP), ] 
rs76Mb<-rs76$BP/1000000 
 
#Draw lines to outline area of interest 
#line1=58261741/1000000 
#line2=58327540/1000000 
 
#define genomic region for plots 
rows<-nrow(chr3) 
r_start<-chr3$BP[1] 
r_end<-chr3$BP[rows] 
r_startMb<-r_start/1000000 
r_endMb<-r_end/1000000 
row_p<-which.min(chr3$P) 
 
#plot association 
#Call quartz window and write to pdf. Name file as you like. 
quartz(width=11,height=8,type="pdf",file="ea_pxk_imputed_not_new_rs46_may.pdf
") 
par(mfrow = c(1, 1), mar=c(5, 5, 5, 5) + 0.1)   
#plot- change xlim as needed- I manually set them for this plot. 
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plot(chr3Mb,-log10(chr3$P),xlab="Chr3 (Mb)",ylab=expression(paste(-
log[10],"(",italic(p),")")),xlim=c(58.15,58.55),ylim=c(0,11),cex=1.5,cex.lab=
1,cex.axis=1,lwd=1,las=1,pch=21,bg="royalblue") 
title(main= "Imputed versus directly typed SNPs") 
legend("right",c("imputed","direct","rs4681677"),pch=21,col="black",pt.bg=c("
royalblue","red","purple")) 
#genome-wide significance line 
abline(h=-log10(5E-8),lty=3,cex=10,col="darkred") 
#Add points for LLAS2 on top of full data 
points(subMb,-log10(sub$P),cex=1.5,pch=21,bg="red") 
#add colored point highlighting SNP of interest 
points(rs76Mb,-log10(rs76$P),cex=2,pch=21,bg="purple") 
 
#Add more parameters for graph- these will be for recombination rate 
par(new=T) 
par(mfrow = c(1, 1), mar=c(5, 5, 5, 5) + 0.1)    
 
#plot recombination rate 
plot(combined3Mb,combined3$COMBINED_rate.cM.Mb.,type="l",xlim=c(58.15,58.55),
ylim=c(0,100),cex=1,cex.lab=1,cex.axis=1,lwd=1.5,xlab="",ylab="",xaxt="n",yax
t="n",col="blue") 
axis(4,cex=1,cex.lab=1,cex.axis=1,lwd=1,las=1,col.axis="blue",col="blue") 
mtext("Recombination Rate (cM/Mb)",side=4,line=2.5,cex=1,col="blue",crt=180) 
 
#define build for biomart 
mart<-useMart("ensembl",dataset="hsapiens_gene_ensembl") 
 
#get list of genes in region 
genes <- 
getBM(attributes=c("ensembl_gene_id","start_position","end_position","exon_ch
rom_start","exon_chrom_end","strand","external_gene_id"),filters=c("chromosom
e_name","start","end"),values=list(3,r_start-
100,r_end+100),mart=mart,checkFilters=FALSE) 
 
#plot genes 
 
#split file by genes 
gene_sets<- split(genes,genes$start_position) 
gene_names <- c(names(gene_sets)) 
 
geneSymbol<- function (CCDS,file,label,dir,... ) { 
  
 exonn<- nrow(CCDS) 
 eStart<-CCDS[1,2] 
 eEnd<- CCDS[exonn,3] 
 hei<- 94 
 eStart<-eStart/1000000 
 eEnd<-eEnd/1000000 
 wid<- 0.25 
 rect(eStart,hei-wid,eEnd,hei+wid,col="dark blue",border=NA) 
  
  
 if(dir==-1){ 
  text(x=(eStart+eEnd)/2,y=hei-4,label,col="dark 
blue",font=3,cex=0.9)  
  arrows((eStart+eEnd)/2+0.008,hei-1.5,x1=(eStart+eEnd)/2,y1=hei-
1.5,length=0.05,angle=20,col="dark blue") 
 } else{ 
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  text(x=(eStart+eEnd)/2,y=hei+4,label,col="dark 
blue",font=3,cex=0.9)  
  arrows((eStart+eEnd)/2-
0.008,hei+1.5,x1=(eStart+eEnd)/2,y1=hei+1.5,length=0.05,angle=20,col="dark 
blue") 
 } 
  
} 
#repeat for all genes in set 
par(new=T) 
for (i in 1:length(gene_sets)){ 
geneSymbol(CCDS=gene_sets[[i]],file=chr3,label=gene_sets[[i]][1,7],dir=gene_s
ets[[i]][1,6]) 
} 
dev.off() 
 
Bash scripts 
In order to meet our goals of simplicity, usability and repeatability, we combine 
multiple steps of our analysis pipeline into bash scripts that can be run on the 
computational cluster. Bash scripts are small computer programs that feed instructions 
to the computational cluster on how many computational resources a given job will 
assigned, which programs will run, and which datasets will be analyzed. Figure 7 is an 
example of a bash script requesting 72 hours of computational time and 4 GB of 
memory. The programs to be loaded are PLINK, GTOOL and IMPUTE2. The first part of 
the program loops through a list of file names in a text file, performing the PLINK 
operations on each file sequentially as listed in the loop. Following the loop, one file is 
run through PLINK, selecting the region of interest. The file set is then converted to the 
format compatible with IMPUTE2 using GTOOL. Imputation is then run on the data in 
IMPUTE2. The files are then re-converted to a PLINK compatible format in GTOOL, and 
then the logistic regression analysis is performed in PLINK. At this point the data are 
ready for visualization and interpretation. 
Figure 7: Bash script written for data cleaning, imputation, and association testing. 
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This script allows for the performance of multiple analytical steps form one submission 
to the computing cluster. Each individual step, including data cleaning, file conversions, 
imputation, and association analysis are contained within the script. This script allows 
the user to run imputation and association testing on a list of datasets simultaneously in 
one step, without needing to intervene at each step for each file. 
 
#!/bin/bash 
#BSUB -W 72:00 
#BSUB -M 4000 
#BSUB -e ./lsf_logs/%J.err 
#BSUB -o ./lsf_logs/%J.out 
 
 
#Load the required applications 
module load plink 
module load gtool 
module load impute 
   
fName="file_names.txt" 
 
OFS=$IFS 
IFS=$'\n' 
 
 
#Data cleaning steps 
for line in 'sed "$fName"' 
do 
name=`echo $line | cut -f1` 
plink --noweb --bfile /data/"$name" --make-bed --geno 0.1 --out 
/data/"${name}_g" 
plink --noweb --bfile /data/"${name}_g" --make-bed --mind 0.1 --out 
/data/"${name}_gm" 
plink --noweb --bfile /data/"${name}_gm" --make-bed --maf 0.01 --out 
/data/"${name}_mm"  
plink --noweb --bfile /data/"${name}_mm" --make-bed --hwe 0.001 --out 
/data/"${name}_mmh" 
done 
 
IFS=$OFS 
 
#Convert the data into a compatible file type 
plink --bfile /data/Omni1_mmh --recode --chr 1 --from-mb 58 --to-mb 59 --out 
/data/OMNI1 
gtool \ 
-P \ 
--family \ 
--ped /data/OMNI1.ped \ 
--map /data/OMNI1.map \ 
--og /data/OMNI1.gen \ 
--os /data/OMNI1.sample 
 
#Impute the association results using the 1000 genomes data 
impute2 -m /database/impute2_reference/genetic_map_chr1_combined_b37.txt \ 
-h /database/impute2_reference/ALL.chr1.haplotypes.gz \ 
-l /database/impute2_reference/ALL.chr1.legend.gz \ 
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-g /data/OMNI1.gen \ 
-int 58e6 59e6 \ 
-buffer 20kb \ 
-iter 30 \ 
-burnin 10 \ 
-Ne 20000 \ 
-call_thresh 0.9 \ 
-o /data/OMNI1.impute2 
 
 
#File conversion step 
gtool \ 
-G \ 
--g /data/OMNI1.impute2 \ 
--s /data/OMNI1.sample \ 
--alleles \ 
--ped /data/OMNI1_imputed.ped \ 
--chr 3 \ 
--map /data/OMNI1_imputed.map \ 
--threshold 0.9 \ 
--sex sex \ 
--phenotype phenotype 
 
#Reformat the file 
awk '{OFS="\t"; print $1, $2, $3, $4}' /data/OMNI1_imputed.map > 
/data/OMNI1_imputed2.map 
  
mv /data/OMNI1_imputed2.map /data/$OMNI1_imputed.map 
 
#Run the association test on the imputed data  
plink \ 
--noweb \ 
--file /data/OMNI1_imputed \ 
--logistic \ 
--covar covar_all.txt \ 
--covar-name admixWA,admixIA,admixAS \ 
--out /data/OMNI1_imputed_log 
 
Another advantage of using basic scripting language to run analysis is the ability 
to run the same analysis on multiple files simultaneously. One specific task that would 
have required weeks for one individual researcher to run is the conditional analysis 
described above. We have developed a strategy to identify the most important variants 
to the association signal by performing the step-wise regression analysis controlling for 
each variant in the region. As some regions after imputation can contain thousands of 
variants, this represents a significant time investment to run each test. We have utilized 
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a bash script to streamline this operation that will loop through each variant in the region 
one by one (Figure 8). The results are then compiled and written to a single file, allowing 
us to quickly identify the variants that control for the association signal to a given 
significance threshold. 
Figure 8: Bash script written for looping through conditional analysis. 
This script allows looping through and conditioning on each possible SNP in the dataset. 
This allows for an unbiased approach to the conditional analysis, where each variant is 
considered independently and with equal weight to all other variants. Each conditional 
analysis that results with residual association for a variant is written into a new file, 
allowing rapid assessment of which variants are able to account for all association in a 
region. 
 
#BSUB -W 24:00 
#BSUB -M 10000 
#BSUB -e ./lsf_logs/%J.err 
#BSUB -o ./lsf_logs/%J.out 
 
#WARNING: run this program within a new, empty directory. 
#Thousands of files will be generated. 
#You need binary plink files and a SNPs.txt file to run this script 
#The SNPs.txt file needs a list of all variants in the file. 
#You can get this from your .bim or .map file. 
#There can only be one SNP per line and not other information.    
 
fName="~/data/SNPs.txt" 
 
#Load required applications 
module load plink 
mkdir ~/data/out/adjusted_for_one_variant 
 
#Adjust for every SNP in a binary plink dataset 
 
for line in $(cat $fName) 
 
do 
   
#NOTE: It is necessary to change this code to reflect your genetic dataset. 
   
  plink --noweb \ 
  --bfile ~/data/dataset \ 
  --logistic \ 
  --covar ~/data/covar.txt \ 
  --covar-name admixWA,admixIA,admixAS \ 
  --hide-covar \ 
  --condition "$line" \ 
  --out "~/data/out/${line}_conditioned" 
   
#Identify all pairs of SNPs capable of removing all association 
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#p<0.01 in a .txt results file 
#NOTE: The level of significance can be adjusted 
   
  awk '$9<=0.01' "~/data/out/${line}_conditioned.assoc.logistic"  
   > "~/data/out/${line}.lessthan0.01" 
 
done 
 
#move all lines from all files with variants that retain significance 
#after adjustment to a new directory 
 
mv *.lessthan0.01 ~/data/out/adjusted_for_one_variant 
   
cd ~/data/out/adjusted_for_one_variant 
 
#This file will contain a line for each file in the directory 
#with the number of lines in each file. 
#Each line contains a variant with residual association. 
wc -l * > ~/data/out/results.txt 
 
By adopting a consistent approach to our dataset analysis, we have the power to 
automate and standardize common tasks. With new datasets can we are able to 
significantly reduce total man-hours on any individual job as the basic tasks can all be 
run quickly and efficiently. In addition, standardization facilitates reproducibility and 
consistency. 
 
Resources 
PLINK- http://pngu.mgh.harvard.edu/~purcell/plink/ 
INPUTE2- https://mathgen.stats.ox.ac.uk/impute/impute_v2.html 
R- http://www.r-project.org/ 
SNPTEST- https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html 
METAL- http://www.sph.umich.edu/csg/abecasis/metal/ 
Haploview-http://www.broadinstitute.org/scientific-
community/science/programs/medical-and-population-genetics/haploview/haploview 
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Chapter 4: Lupus risk variants in the PXK locus alter B-cell 
receptor internalization 
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Abstract 
Genome wide association studies have identified variants in PXK that confer risk for 
humoral autoimmune diseases, including systemic lupus erythematosus (SLE or lupus), 
rheumatoid arthritis and more recently systemic sclerosis. While PXK is involved in 
trafficking of epidermal growth factor Receptor (EGFR) in COS-7 cells, mechanisms 
linking PXK to lupus pathophysiology have remained undefined. In an effort to uncover 
the mechanism at this locus that increases lupus-risk, we undertook a fine-mapping 
analysis in a large multi-ancestral study of lupus patients and controls. We define a 
large (257kb) common haplotype marking a single causal variant that confers lupus risk 
detected only in European ancestral populations and spans the promoter through the 3’ 
UTR of PXK. The strongest association was found at rs6445972 with P < 4.62 x 10-10, 
OR 0.81 (0.75 – 0.86). Using stepwise logistic regression analysis, we demonstrate that 
one signal drives the genetic association in the region. Bayesian analysis confirms our 
results, identifying a 95% credible set consisting of 172 variants spanning 202 kb. 
 
Functionally, we found that PXK operates on the B-cell antigen receptor (BCR); we 
confirmed that PXK influenced the rate of BCR internalization. Furthermore, we 
demonstrate that individuals carrying the risk haplotype exhibited a decreased rate of 
BCR internalization, a process known to impact B cell survival and cell fate.  
 
Taken together, these data define a new candidate mechanism for the genetic 
association of variants around PXK with lupus risk and highlight the regulation of 
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intracellular trafficking as a genetically regulated pathway mediating human 
autoimmunity.   
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Introduction  
Systemic Lupus Erythematosus is the prototypical systemic autoimmune disease. 
Consequently, considerable effort has been devoted to understanding the genetic 
component of lupus risk. Now an understanding of causal mechanisms is approaching 
10% of the 50 replicated genomic risk-loci that reach genome-wide significance [128].  
Using a genome-wide association study (GWAS) design, we first identified association 
of a single nucleotide polymorphism (SNP) in the PXK locus with the occurrence of 
lupus in women of European descent [142]. The PXK locus association with lupus-risk 
has since been replicated in several studies [143, 185]. In these studies, the same 
variant identified in the initial GWAS was assessed in independent cohorts and the 
lupus-risk association was replicated [143, 185]. These studies did not include any 
biological or functional genomic follow-up of the replicated association of this variant 
[143, 185].  A fourth, recent study included a moderately powered fine mapping analysis 
of a European cohort and used expression quantitative trait locus analysis of nearby 
genes to argue for a role of ABHD6 in the increased lupus risk. For the current analysis, 
we initiated a well-powered fine-mapping study aimed at identifying the likely causal 
variants and defining the biological mechanisms of lupus risk at this locus. 
PXK is part of the sorting nexin (SNX) family of proteins, which are important for 
receptor internalization, organelle trafficking including endosomal trafficking, and other 
membrane-centric sorting functions. This is accomplished primarily through the PX-
domain mediated binding of PI3P [134, 348]. PXK was first identified and cloned by two 
independent groups in 2005 [132, 349]. Initial studies established that PXK is detectable 
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in most tissues with a primarily cytoplasmic distribution. A more recent study in COS-7 
cells demonstrated that PXK co-localized with the EGFR. Furthermore, PXK facilitated 
EGFR internalization following ligand binding, which was found to be PX-domain 
dependent [141, 350]. PXK is widely expressed in the brain and blood [132], especially 
in B cells (Figure S1). 
In this study, we identify a 257 kb region on chromosome 3, including all of PXK and a 
large region upstream of the gene that contains the lupus association signal. These 
results are confirmed via Bayesian analysis by which we identify a credible set 
consisting of 172 variants that explain 95% of the posterior probability in the region 
[343]. Through step-wise logistic regression analysis, we demonstrate that this region 
contains a single genetic effect.  
Many studies in mice and humans highlight a central role of B cells in the etiology of 
lupus. Using the transcriptome of various B cell subsets, Hu et al. demonstrated that B 
cells and especially transitional B cells are enriched for transcripts near genetic variants 
associated with increased lupus risk [246]. Autoreactive B-cells play a critical role in the 
development of autoantibodies that lead to immune complex deposition and lupus-
associated tissue damage [351]. In murine studies, mice without B cells are largely 
protected from lupus-like disease [352]. Furthermore, murine studies established a clear 
role for B cells in the dysregulated cytokine production and T cell activation associated 
with lupus-like autoimmunity [353, 354].  
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B cell signaling through the B cell receptor (BCR) plays a critical role in the development 
of autoimmunity in lupus [355, 356]. For example, BCR internalization facilitates Toll like 
receptor ligand internalization and signaling. Furthermore, type I IFN- a key cytokine 
known to play a role in lupus- is known to promote rapid B cell receptor internalization 
[357, 358]. Based on its role in regulating EGFR, we hypothesized that PXK participates 
in BCR internalization and lupus-associated variants in the PXK locus differentially 
regulate BCR internalization. Indeed, we demonstrate that PXK colocalizes with the 
BCR and that the risk variants are associated with a decrease in BCR internalization. 
Knockdown of PXK replicates this phenotype, confirming the direct involvement of PXK 
in BCR trafficking. 
 
Methods 
Subjects and Study Design 
We used a large collection of samples from case-control subjects from multiple ethnic 
groups. These samples were from the collaborative Large Lupus Association Study 2 
(LLAS2) [338] and were contributed by participating institutions in the United States, 
Asia, and Europe. According to genetic ancestry, subjects were grouped into ethnic 
groups including European American (EU), African American (AA), Asian and Asian 
American (AS), and Hispanic American (HA). Informed consent was obtained from all 
subjects using Institutional Regulatory Board approved consent documents. All lupus 
patients met the American College of Rheumatology (ACR) criteria for the classification 
of lupus [24].  
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Genotyping of genetic variants and Sample Quality Control 
We genotyped 58 single-nucleotide polymorphisms (SNPs) covering the entire PXK 
region (58.1-58.5 MB on Chr 3, Build 37), as part of a larger custom genotyping study. 
The variants were chosen based upon the results of a candidate association study of 
720 women of European ancestry and 2,337 controls [142]. Specifically, the variants 
were chosen to span the association interval identified with the Infinium HumanHap330 
array. Genotyping of SNPs was completed with Infinium chemistry on an Illumina iSelect 
custom array according to the manufacturer’s protocol. The following quality-control 
procedures were implemented to identify SNPs for analysis: well-defined clusters for 
genotype calling, call rate >90% across all samples genotyped, minor allele frequency 
(MAF) >1% (except for the rare variant analysis as described below), and p>0.05 for 
differential missingness between cases and controls (the total proportion missing was 
<5%). One marker with evidence of a departure from Hardy-Weinberg proportion 
expectation (p<0.0001 in controls) was removed from the initial analysis.  
 
We removed individuals with a call rate <90% or excess heterozygosity. The remaining 
individuals were examined for excessive allele sharing as estimated by identity-by-
descent (IBD). In sample pairs with excessive relatedness (IBD>0.4), one individual was 
removed from the analysis on the basis of the following criteria: (1) remove the sample 
with the lower call rate, (2) remove the control and retain the case, (3) remove the male 
sample before the female sample, (4) remove the younger control before the older 
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control, and (5) in a situation with two cases, remove the case with the less complete 
phenotype data available. Discrepancies between self-reported and genetically 
determined gender were evaluated.  
 
Ascertainment of Population Stratification 
Genetic outliers from each ethnic and/or racial group were removed from further 
analysis as determined by principal component (PC) analysis and admixture estimates 
(Figure 1 of ref [241] and ref [131, 359]). We used 347 ancestral informative markers 
(AIMs) from the same custom genotyping study that passed quality control in both 
EIGENSTRAT [131] and ADMIXMAP [130, 360] to distinguish the four continental 
ancestral populations, allowing identification of the substructure within the sample set 
[129, 361]. The AIMs were selected to distinguish four continental ancestral populations: 
Africans, Europeans, American Indians, and East Asians. We utilized principal 
components from EIGENSTRAT outputs to identify outliers of each of the first three PCs 
for the individual population clusters with visual inspection. 
 
Statistical Analysis - Workflow 
The analysis was initiated by assessing the association of genotyped variants in each of 
the four ancestral cohorts individually as done previously at another locus [362]. 
Strategically, we analyzed the genotyped, then imputed variants, performed full 
haplotype analysis, executed linkage disequilibrium analysis, and finally built a statistical 
model to account for the lupus-associated variability in European ancestry. In building 
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the model of association in European Americans, we comparatively evaluated every 
variant in the region for its ability to better account for the lupus-associated genetic 
variation. 
 
Statistical Analysis - Frequentist approach 
We tested each genetic variant for association with lupus using logistic regression 
models (frequentist approach) that included three admixture proportion estimates as 
covariates as implemented in PLINK v 1.07 [339, 340]. The additive genetic model is the 
primary model of inheritance. Other models were subsequently considered, but only if 
substantially superior. We performed a Cochran-Armitage trend test, a genotypic test, 
and tested both the dominant and recessive gene models. Logistic regression using an 
additive model remained the best model. 
Step-wise logistic regression was performed to identify those genetic variants 
independently associated with the development of lupus in PLINK. For these analyses, 
the allelic dosage of a specific variant was added to the logistic model as covariates in 
addition to the admixture estimates. Haplotypic associations were assessed using 
logistic regression incorporating admixture measurements as covariates.  
Linkage disequilibrium (LD) and haplotypes were determined with PLINK and 
HAPLOVIEW v 4.2 [363-365]. We calculated haplotype blocks for those haplotypes 
present at >3% frequency using the 4 gamete rule algorithms with a minimum r2 value of 
0.8. Haplotypic associations were performed in PLINK using a 200 kb sliding window 
approach.  
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Statistical Analysis - Bayesian approach 
Using SNPTEST, we calculated the Bayes factor (BF) for each genetic variant: the 
probability of the genotype configuration at that genetic variant in cases and controls 
under the alternative hypothesis that the variant is associated with disease status 
divided by the probability of the genotype configuration at that variant in cases and 
controls under the null hypothesis that disease status is independent of genotype at that 
variant as previously described (we used the methods developed and introduced in ref 
[343]). We used three admixture estimates as covariates, as we did for the frequentist 
approach. Large values of the Bayes factor (BF) correlate to robust evidence for 
association, as small p-values correlate to strong evidence in a frequentist approach. 
For our well-powered study, the Bayes factors (BFs) of the variants were highly 
correlated with the p-values (consistent with ref [366]). We used the additive model. The 
linear predictor is log(pi/(1-pi)) = µ + ßGi, and the prior is µ~N(0,12), ß~N(0,0.22) 
(variables are defined in the supplementary note in ref [343]). 
To identify the variants most likely to be driving the statistical association we calculated 
a posterior probability under the assumption that any of the variants within a single 
genetic effect could be causal and that only one of these variants is causal for each 
genetic effect. Variants with a low posterior probability are highly unlikely to be causal 
regardless of the allele frequency or presence of the actual causal variant in the 
analysis, following the procedure as presented [343]. 
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Re-sequencing 
We re-sequenced the PXK region as described previously [347]. DNA from European 
American subjects included in the current genotyping experiment was sequenced. To 
assess the accuracy of sequence-based SNP calling, we cross-referenced the 
sequenced and genotyped allele calls. Briefly, 3–5 micrograms of whole genomic DNA 
from each sample was sheared and prepared for sequencing with an Illumina Paired-
End Genomic DNA Sample Prep Kit. Targeted regions of interest from each sample 
were then enriched with a SureSelect Target Enrichment System utilizing a custom-
designed bait pool (Agilent Technologies). Post-sequence data were processed with 
Pipeline software v.1.7 (Illumina). All samples were sequenced to minimum average fold 
coverage of 253. Variant detection and quality control were also performed as 
previously described [347]. 
 
Imputation to composite 1000 Genomes reference panel 
To detect associated variants that were not directly genotyped, we imputed the PXK 
region with IMPUTE2 and using a composite imputation reference panel based on 1,000 
Genomes Project sequence data freezes from December 2013 [245, 340, 344]. Imputed 
genotypes were required to meet or exceed a probability threshold of 0.5, and 
information measure of >0.4, and the same quality-control criteria threshold described 
for the genotyped markers. In the statistical analyses, the probability threshold from 
each imputed value was incorporated into the statistical analysis using SNPTEST. The 
overall genotype-imputed variant concordance rate was >93%.  
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Rare variant analysis 
Rare variant analysis was performed in SVS Golden Helix SNP & Variation Suite 
v7.6.10 on the re-sequenced dataset and the imputed dataset. Rare variants were 
filtered based upon call rate and minor allele frequency <0.01. The one-sided kernel 
based adaptive cluster algorithm was performed using the hyper geometric kernel type 
with 1000 permutations in SVS GoldenHelix. For these studies, the initial analysis was 
performed using sequencing data from 92 lupus cases and 114 controls. Because this 
initial study was underpowered to identify an increased rare variant burden, we 
extended this analysis to an imputed dataset of all 4220 European lupus cases and 
3803 European lupus controls. The accuracy of rare variant imputation, while limited, 
has been previously validated [367, 368].  
 
Power analysis 
Power analysis was performed using the Genetic Power Calculator [369]. 
 
Cell culture 
Lymphoblastoid cell lines (LCLs) derived from control study participants without lupus 
were generated as previously described [338] and maintained at 37° in RPMI 1640 
media containing 10% heat-inactivated fetal bovine serum (FBS) and anti-biotic/anti-
micotic (Gibco/Life Technologies, Grand Island, NY). Peripheral blood mononucelar 
cells (PBMCs) were isolated using Ficoll-gradient centrifugation in SepMate tubes 
 87 
(Stemcell Technologies, Vancouver, BC, Canada) from fresh blood collected in acid 
citrate dextrose (ACD) tubes with informed consent from healthy donors. B cells were 
isolated using the B-cell isolation kit-II (Miltenyi Biotech, Auburn, CA).  
 
RNA purification and expression analysis 
Total RNA was purified from LCLs using the RNeasy kit (Qiagen Valencia, CA). RNA 
was reverse-transcribed with the High-Capacity RNA-to-cDNA kit (Applied Biosystems, 
Grand Island, NY). Gene expression was determined by real-time PCR using a 7500 
Real-time PCR system or Viia 7 system (Applied Biosystems). Relative quantification 
was calculated by the comparative CT method [370]. Briefly, expression levels for each 
target were normalized to levels of 18S in the same well. All samples were then 
normalized to a selected sample and the data was exponentially transformed. 
 
Protein expression was quantified in LCLs by flow cytometry. Cells were permeabilized 
and stained using reagents from Beckton, Dickinson and Company (BD, Franklin Lakes, 
NJ). Following staining, fluorescence was determined on an LSRFortessa analyzer 
(BD). The geometric median fluorescence intensity (gMFI) was calculated in FlowJo 
(Tree Star, Ashland, OR) and used as an estimate of protein expression. All 
experiments were run in triplicate. Statistical analysis and data visualization were done 
with GraphPad Prism (GraphPad Sftward, La Jolla, CA). 
 
BCR internalization and colocalization 
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BCR internalization was adopted from the method described by Malhotra et al [371, 
372]. Briefly, LCLs or freshly isolated PBMCs from subjects without lupus were 
incubated with anti-BCR for 30 min at 4° Celsius. Cells were then placed at 37°C for the 
indicated times. Cross-linked BCR remaining on the surface was then detected with 
fluorescently labeled secondary antibody with the LSRFortessa Cell Analyzer. Percent 
internalization was obtained by measuring the GMFI at each time point and then 
calculating the change as follows: (gMFI no internalization (4°. sample) – gMFI 
internalization (37°. sample)) ÷ (gMFI no internalization (4°. sample)) x 100. Statistical 
analysis was performed in R using the packages “nlme” and “lmerTest”. Cells were 
imaged with a confocal microscope and the ImageStreamX (Amnis, Seattle, WA) for co-
localization analysis. All experiments were run in triplicate. 
 
shRNA transfections 
shRNA were obtained from the CCHMC Lenti-shRNA Library Core, utilizing the Sigma 
Mission system. Viral vector DNA was isolated using Endofree Plasmid Maxi Prep kits 
(Qiagen). Lentiviral transduction was performed by the CCHMC Viral Vector Core. Viral 
particles containing the shRNAs were used to transfect LCLs from control subjects. 
Cells were plated onto retronectin-coated plates, viral particle supernatant added, and 
spun for 45 min at 1300 x G at 22°C. After resting at 37°C overnight, spinfection was 
repeated. Cells were transferred to selection media containing 2 ug/ml puromycin after 
48 hrs. After non-transfected cells began to die (approximately 3-5 days) cells were 
tested for PXK expression and maintained for use in subsequent experiments. 
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Materials 
Anti-BCR (F(ab’)2 antibodies to IgG/IgM and Alexa Fluor 647-conjugated donkey anti-
human IgG/IgM) were from Jackson ImmunoResearch (West Grove, PA). Anti-PXK 
antibody was purchased from Abcam (Cambridge, MA). Anti-LAMP1 antibody was 
purchased from BioLegend (San Diego, CA). Secondary antibodies were purchased 
from Life Technologies (Carlsbad, CA). Retronectin was purchased from Clonetech 
(Mountain View, CA). Puromycin was purchased from Invivogen (San Diego, CA). All 
other antibiotics and cell culture reagents were purchased from HyClone (Logan, UT) 
and Gibco (Life Technologies). Quantitative PCR was performed using TaqMan probes 
from Life Technologies. 
 
Results 
We genotyped 57 useful markers from the PXK locus in a transancestral group of 
18,286 lupus cases and controls. Our study included 8,023 individuals of European 
descent (EA), 3,740 individuals of African American descent (AA), 2,481 individuals of 
Hispanic American descent (HA) and 2,652 individuals of Asian descent (AS). To better 
capture the total variation in the locus, we imputed against a composite reference panel 
derived from the 1000 Genomes Project [373] for a final dataset of 269-835 variant 
markers, depending on ancestry, all with a minor allele frequency (MAF) greater than 
0.01 (Table 5).  
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Table 5. Summary statistics for each study population. Cleaning steps are described in 
methods. 
 
We performed logistic regression analysis to reveal a large association region of 257 kb 
extending from just upstream of PXK beginning in ABHD6 and extending through 
RPP14 in individuals of European descent (Figure 9a). Overall, the most significant SNP 
was rs6445972 with P < 4.62 x 10-10, OR 0.81 (0.75 – 0.86). The most significant, 
directly genotyped SNP was rs4681677 with P < 2.00 x 10-9, OR 0.81 (0.76 – 0.87). 
Because rs4681677 was genotyped and not assessed solely through imputation, we 
used this SNP to classify cell lines as risk or protective for subsequent biological 
experiments. We found no evidence of the lupus-association at this locus in the other 
populations studied (Figure 9b). rs6445972 has an allele frequency of 30.0% in the EA 
cohort, 10.4% in the AA cohort, 22.9% in the HA cohort, and 0.2% in the AS cohort, 
suggesting that a largely European-derived allele is driving the very modest statistical 
association in the cohorts with European admixture.  
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Analysis of 
linkage 
disequilibrium 
(LD) in the region 
revealed high LD 
between the most 
strongly 
associated 
variants (Figure 
10a). No single 
haplotype (using 
either blocks 
constructed from 
continuous groups 
of variants or the 
most highly 
associated 
variants) 
outperformed the 
single variant 
association model 
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(data not shown), 
supporting the 
conclusion that 
the association in 
the region is due 
to a single genetic 
variant. In a 
complementary 
Bayesian 
analysis, we find a 
similar pattern of 
association, 
consistent with 
results from our 
frequentist logistic 
regression 
analysis. The 95% 
credible set [343] 
contains 172 
variants spanning 
a 202 kb region (chr 3: 58261741-58463411) (Figure 10b). 
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To identify candidate variants in the EA population, we performed stepwise logistic 
regression to evaluate the ability of variants within the associated haplotype to explain 
all of the lupus-associated variation. Adjusting for any one of the top variants in the 
region eliminated the association signal, supporting the model that there is only one 
association in the 
region (Figure 11). 
We sequentially 
tested each 
variant in our 
dataset 
individually in our 
conditional 
analysis in an 
attempt to isolate 
groups of variants 
that may disproportionately carry the association signal in the region. While we did find 
clear groups, we found those variants that were able to adjust for the largest portion of 
the lupus-associated variation were in high LD (r2>0.8) with the most strongly 
associated variants. Notably, the SNP identified in our original GWAS study, rs6445975, 
did not account for lupus risk as completely as the most strongly associated variants in 
the current study (Figure 11 and Figure S2). 
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It remained possible that rare variants were driving the lupus association at the PXK 
locus. To test this possibility, we performed deep sequencing of the region in 92 cases 
and 114 controls of European ancestry. We found no statistical association of any of the 
variants with frequencies less than one percent using a logistic regression analysis with 
an additive model; furthermore, we found no increased burden of rare variants in any of 
the genes in the region in the cases compared to the controls (data not shown). Despite 
the limitations of imputed rare variants, 
we repeated the rare variant burden 
test on the complete European 
population and did not find evidence of 
increased rare variants in the lupus 
cases. 
 
In order to assess the hypothesis that 
lupus-associated variants were 
affecting the gene expression, we 
measured expression levels of all 5 
genes in transformed B cell lines from 
control subjects and found no 
difference between cell lines with 
homozygous risk and homozygous 
non-risk genotypes (Figure S3). We 
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did not find any difference in mRNA or total PXK protein expression (Figure 12A-B). 
PXK is highly expressed in the B cell lineage, with the highest expression in mice 
observed in both transitional and follicular splenic B cells [246]. The transitional B cell 
was recently implicated as one of the cell types critical to lupus pathogenesis based on 
a combined genetic and cell-specific expression analysis [374]. Given the expression of 
PXK in B cells, the fact that PXK has 
been shown to play a role regulating 
cell surface receptor expression, and 
the importance of B cells to the 
pathology of lupus, we hypothesized 
that PXK participates in the 
internalization of the BCR. We first 
evaluated colocalization between PXK 
and the BCR in B cells following BCR 
crosslinking on the cell surface. We 
found moderate steady-state 
colocalization between PXK and the 
BCR at baseline that increased 
following BCR crosslinking and 
continued to increase with cellular internalization (Figure 13). We then tested the 
hypothesis that the lupus-associated risk variants at the PXK locus affected the rate of 
BCR internalization by measuring the internalization of the BCR in cells derived from 
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individuals with known genotypes. Following BCR crosslinking, we measured receptor 
internalization with flow cytometry and found that cells carrying the homozygous risk 
genotype displayed a decrease in the amount of BCR internalization compared to cells 
homozygous for the protective genotype (Figure 14). This finding was consistent across 
all the measurements over the time 
course of the experiment. 
To assess the role of PXK in the BCR 
internalization phenotype, we 
decreased PXK expression using 
shRNA by transfecting 5 study-derived 
cell lines from patient without lupus 
with shRNA targeted against PXK or 
scrambled controls (Figure 15A). 
Knockdown of PXK resulted in 
reduced internalization of the BCR, 
especially at the early time points 
(Figure 15B), and this reduction was 
directly correlated with PXK 
expression (Figure 15C). 
 
Discussion 
We performed a fine-mapping study to 
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define the genetic variants and the gene 
most likely to be causal for increased 
lupus risk. We genotyped 18,286 cases 
and controls from four ancestral 
populations, leveraging imputation to 
increase our coverage of the target 
locus. We used both logistic 
regression,and Bayesian methods to 
verify our findings that the disease risk 
from this locus is due to highly 
correlated variants in a large region 
including PXK. Additionally, we 
complemented our genetic fine-mapping 
with biological experiments, identifying a 
genotypic change in B cell receptor 
internalization that is associated with the 
presence of lupus-risk variants. 
 
Analysis of the PXK locus in non-
European populations revealed no 
significant association in the region 
(Figure 9B). The allele frequency of the 
 98 
most highly associated variants differed amongst the ancestral groups, and given the 
observed allele frequencies, power analysis indicates that a much larger non-European 
population will be needed to detect a similar association of this magnitude at this locus 
(data not shown). Thus the lack of an association in the other populations may be due 
entirely to the difference in power. 
 
We found a 50% decrease in BCR internalization kinetics between risk and non-risk 
genotypes. This change in BCR internalization may have a small effect in the regulation 
of B cell signaling; however, it could also be meaningful in the context of other additive 
changes to the B cell signaling pathway [128]. There are several mechanisms through 
which this functional change could affect the risk of autoimmunity. For example, stimuli 
that would be sufficient to develop strong B cell activation with subsequent negative 
selection may now be less likely to result in elimination due to attenuated BCR 
internalization. Indeed, the persistence of auto-reactive clones in the periphery may play 
an important role in the context of lupus pathogenesis. 
 
PXK colocalized with the BCR and affected internalization, indicating a potential role for 
PXK in the regulation of BCR signaling. Importantly, the colocalization increased as the 
BCR is internalized into the cell, suggesting a role for PXK beyond the cell surface. 
Furthermore, we find that cells carrying the lupus-risk haplotype have a decreased 
amount of BCR internalization when compared to cell lines carrying the non-risk 
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haplotype, an allelic functional change that we present as a candidate causal 
mechanism of increased lupus risk at this locus. 
 
When PXK is specifically knocked down using shRNA, BCR internalization is 
decreased, confirming a clear role for PXK in regulating BCR internalization. These 
results support the conclusion that the allele-specific changes in BCR internalization we 
detect are most likely attributable to PXK. We do not yet understand the genetic 
mechanism behind this alteration in BCR internalization. We were unable to detect a 
difference in overall PXK expression. It may be that some other molecular differences 
are occurring after PXK expression, such as alternative splicing or differential 
posttranslational modification. Future studies will be directed at detecting these 
changes. While ABHD6 eQTLs were shown to correlate with lupus-association, there 
were also PXK eQTLs that were associated with lupus [149]. The PXK locus remains 
complicated and future work will be important to continue to unravel the specific genetic 
variations underlying the lupus association. 
 
We and others refer to this locus as the “PXK locus” [142, 149, 185, 298, 374]. Although 
our step-wise logistic regression analysis of common variants (Figure 11) makes it 
unlikely, it is still possible that there is a contribution of rare variant(s) that we missed. 
Of the 5 genes in the region, PXK and DNase1l3 are the only genes with appreciable 
expression in immune cells based on evaluation of public databases (data not shown). 
DNASE1L3 encodes the protein DNase 1-like 3, and is the only gene that has been 
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investigated functionally in the context of lupus. A loss-of-function frameshift mutation in 
DNASE1L3 was found to be associated with early-onset lupus and lack of detectable 
DNASE1L3 transcripts in an autosomal recessive manner in six families of Arab 
descent [375]. DNASE1L3 was also recently identified as a risk gene in systemic 
sclerosis [376]. The variant identified in that study shows no association with lupus in 
our dataset (p=0.3067). DNASE1L3 is removed from the peak association in the 
frequentist, logistic regression analysis and no members of the 95% credible set in the 
Bayesian analysis were located in or within 25kb of DNASE1L3. It remains possible that 
variants many hundreds of killobases away from the promoter of a gene could affect 
that genes transcription [377]; however, while both of our groups found detectable 
DNASE1L3 transcripts, neither our group nor other groups have identified allelic 
expression of DNASE1L3 in our cell lines [149]. Of the remaining genes, ABHD6 has 
recently been suggested as the causal gene responsible for the association with lupus 
at this locus [149]. Mutations in ABHD6 have been associated with multiple non-
autoimmune phenotypes [378-382], but beyond ABHD6 being in the associated region 
there is no evidence, at present, for ABHD6 in lupus pathogenesis. 
 
Overall, we identified a limited haplotype of highly associated variants in the promoter 
and first exon of PXK that account for all of the lupus-association in the region. We 
performed biochemical analysis to demonstrate that PXK co-localizes with the BCR and 
affects BCR internalization. Furthermore, we identified an allelic decrease in PXK-BCR 
co-localization and BCR internalization in subjects expressing the lupus-risk haplotype. 
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Taken together, our work supports a model in which PXK increases lupus risk through 
the regulation of BCR internalization. 
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Autoimmunity is a failure of homeostasis. In lupus, the clinical evidence of that 
loss of balance is readily apparent, but the specific pathophysiologic mechanisms 
leading to disruption of homeostasis are still being elucidated. Especially with the 
increase in data available in this era of genomic exploration, an increasing number of 
molecular pathways and mechanisms are being identified. The work presented in this 
dissertation focuses on the PXK locus and the genetic and biologic evidence we find 
supporting this locus as a potentially important player in the maintenance of balance in 
the immune system, and in B cells in particular. 
The results of our fine-mapping study clearly support the association of a ~200kb 
region extending from the promoter of PXK through to the 3’ UTR in European ancestral 
populations. Stepwise logistic regression supported the conclusion that there is only one 
independent association signal in the region, and the Bayesian analysis confirmed our 
results. The 95% credible set contains 172 variants in a 202 kb region. The association 
that we identify is confirmed by another, smaller, recent study that also demonstrated a 
very comparable pattern of association with similar boundaries and LD amongst the 
most associated variants [149]. Ideally, a fine-mapping study will allow a narrowing 
down of potential causal variants and highlight a specific genomic region likely to 
contain the casual variant. While we were able to identify a specific, well-defined region 
of the genome associated with SLE, which replicates the findings from another, 
independent, dataset, the 95% credible set still contains nearly 200 variants and the 
genomic region is ~ 200 kb in length. Further refinement of the genetic signal in this 
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locus will be crucial to fully understanding the exact genetic mechanism underlying the 
SLE association. 
 
The Search for a Causal Variant 
The first step we took in trying to identify the causal variant in the PXK region 
was conduct a multi-ancestral fine-mapping study. Even with the large number of 
subjects in our study, it is becoming apparent that even larger numbers are necessary 
for multi-ancestral analysis [383, 384]. Our power analysis suggests that to detect an 
effect of a similar size to that in the EA ancestry, we would need at least twice as many 
subjects. Another potential limitation of our current study was the number of variants 
typed in the PXK locus. 57 markers were included in the analysis, covering 
approximately 300kb of the target locus. We used imputation to increase our coverage 
of the region, including an additional 10,000 markers covering over 1MB of DNA in the 
region. Most of these markers were non-polymorphic in some samples and were 
eliminated from further analyses, leaving us with 835 variants total in the EA samples 
across the 300kb primary region. While this represents a more than 10-fold increase 
from our directly genotyped markers, and also represents the most complete set we 
have to date of the catalogued common variants in this region, we may still be missing 
the causal variant. One possible explanation is that the actual causal variant is rare, and 
only occurs in a subset of patients and yet the association in that subset is strong 
enough to drive the association in the entire data set. This is very unlikely given the 
small effect size of the association we have identified at the PXK locus. It could also be 
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that the causal variant does exist within our pool of variants, but given the limited nature 
of current variant annotation, we may not fully appreciate the variant. 
 
Defining a causal variant 
What is a causal variant? A causal variant is the specific genetic change that is 
responsible for the biological change that increases disease risk at an associated locus. 
Given that most disease-associated genetic variants only account for a small proportion 
of the absolute risk of acquiring a given complex genetic disease, any single causal 
variant is most likely not responsible for the entirety of the disease phenotype. Instead, 
in combination with other, similar genetic changes, or given specific environmental 
exposures, the causal variant at the associated locus increases the likelihood of 
acquiring the disease. In order to be casual in the context of a specific disease then, the 
suspected variant will lead to some biological alteration that favors disease. For 
autoimmune diseases such as lupus, the identified and suspected variants often lead to 
disease-permissive alterations to the immune system (e.g. small amplifications of the 
Type I IFN inflammatory signaling pathway). 
In the context of the PXK locus, we approached the problem from two directions 
simultaneously- from the genetic side by attempting to refine the lupus-associated 
genetic signal to the smallest number of potential candidates, and the from phenotypic 
side, identifying a variant-linked intermediate phenotype with a potential impact on 
disease pathology. 
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Criteria for causality 
A recent study outlines criteria that have been successfully used to tie discovered 
variants in single patients with immunodeficiency to Mendalian disorders [385]. First, the 
variant must be completely penetrant, meaning it occurs in individuals displaying the 
phenotype, and not in those that do not display the phenotype. Secondly, mechanistic 
studies must demonstrate a direct alteration of protein expression or function because 
of the genetic variant. Lastly, a causal relationship must be established between the 
genetic variant and the clinical phenotype either through a relevant cellular or animal 
model. The first requirement is obviously not applicable to complex genetic diseases as 
by definition, there is not a single genetic variation responsible for the clinical 
phenotype. In fact, even rare variants with potentially large effects may have variable 
penetrance in the complex disease model depending on the background genetic liability 
[386]. 
For various reasons this is likely to be more successful in Mendalian disorders 
where a single variant in one gene is responsible for the disease phenotype. In 
polygenetic disorders with environmental contribution, such as lupus, it becomes much 
harder to precisely implicate a functional variant with the disease. In fact, in many 
instances, multiple functional variants will be discovered in a given locus, especially in a 
region that has been extensively studied, and yet these variants may still be incidental 
to the specific disease risk. This appears to be true at the IRF5 locus, which has been 
extensively studied and multiple functional variants described and linked to autoimmune 
diseases such as lupus [387-389], RA [212, 390], systemic sclerosis [391], and MS 
 111 
[392, 393]. We find however that both frequentist and Bayesian analysis on a larger 
trans-ancestral dataset reveal that the most likely causal variants are unrelated to the 
previously described functional variants [394]. This is also the case in the PXK locus, 
where previous studies have identified variants in DNAse1l3 that are correlated with 
DNase1l3 expression. In our dataset we find that these variants are not likely to be 
responsible for the association signal that we see. We make this conclusion based on 
multiple analyses, but especially on the results of the Bayesian analysis, which 
effectively excludes these variants from further consideration. 
 
Investigating Rare Variants 
Rare variants have been proposed to be the source for the missing heritability of 
genetic association studies [395] and as likely causal variants in high LD with tagging 
SNPs identified directly by the study. Theoretically, rare variants would be infrequently 
found in the population, but their disease association would be much more significant 
than the tagging SNPs in high LD as they would be responsible for the actual causal 
mutation. While this certainly may be true, initial studies utilizing exon sequencing have 
not demonstrated to date strong association signals amongst rare variants [396]. The 
exact nature of the contribution of rare variants is currently unclear and there is some 
argument that the amount of missing heritability is overstated, suggesting that rare 
variants with significant disease associations are in fact not common, and instead 
genetic interaction networks may be more prominent in explaining genetic inheritance of 
disease associated genes [248]. A further difficulty with rare variant analysis is the large 
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number of samples needed for adequate power given the small effect size [384, 397]. 
For example, one estimate for adequate sample size for rare variant analysis in Crohn’s 
disease was 25,000, and to begin to tease out gene-gene, gene-environment 
interactions, that increased to as many as 500,000 subjects [384]. For complex traits, 
such as risk of RA (and SLE), both rare variants and accumulation of multiple common 
variants with small effect sizes, both in the non-coding region, appear to be important 
contributors to overall genetic risk of disease [397]. 
 
Differences in expression 
In addition to rare variants, it may be that we have identified the causal variant, 
but do not yet appreciate its mechanism of action. One obvious disease-modifying 
phenotype to be associated with a variant (thus conferring “causality”) is a change in 
mRNA or protein expression. We did not find any evidence in our current study, with 
some limitations. The first is sample size. Given the relatively small odds ratio (OR) with 
this association, it is likely that any change in expression will not be large. A quick 
power calculation suggests that to identify a 20% difference in expression with an alpha 
of 0.05 with 80% power, we would need 100 samples in each group, for 200 samples 
total. Thus, we were underpowered to detect a modest change in expression. Another 
limitation is that we relied on lymphoblastoid cell lines (LCLs) for our expression 
analysis. LCLs have been shown to differ in expression profiles from peripheral B cells 
[398]. The other advantage to using fresh PBMCs is the ability to measure expression in 
multiple cellular subsets. While we did not find any differences in PXK levels in 
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peripheral B cell subsets in a small sample of healthy controls, the data from the 
Immgen project using murine cells demonstrated the highest level of PXK in follicular B 
cells. It would be valuable to look at differences in PXK expression in B cell subsets 
from genotyped patients and controls.  
A recent paper looking at SLE-associated variants in CSK demonstrated that the 
associated variant affects B cell signaling and activation, leading to changes in B cell 
subset distributions [224]. They found that CSK levels were highest in naïve and 
transitional B cells, and that the risk haplotype correlated with increased CSK 
expression. In naïve B cells, the risk haplotype was associated with increased B cell 
activation. Additionally, they also found higher levels of transitional B cells in cord blood 
from subjects carrying the risk haplotype. This study illustrates some of the additional 
information that can be gained by utilizing fresh patient samples. 
 
Data Integration in the –omics era 
Future work at identifying causal variants will increasingly depend on collecting 
more complete biological samples from large numbers of patients and controls in order 
to properly study the myriad potential consequences of genetic variation including 
changes in overall protein expression, protein function, expression kinetics, protein 
localization (both cellular and sub-cellular), alternative splice products, etc., all in the 
relevant biological environment. One potential approach is described below. 
 
Deep sequencing in combination with SNP genotyping 
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Firstly, comprehensive genotyping information is crucial to ensure proper 
coverage of the risk locus. A combined approach utilizing well-designed and well-tested 
genotyping arrays capable of typing millions of variants per sample can be combined 
with deep sequencing of the identified locus and the surrounding genetic neighborhood 
to ensure identification of all potential variants in the region. Given the greater expense 
of deep sequencing when compared to array-based genotyping, sequencing can be 
performed on a smaller subset of individuals and the resulting data can be used as the 
reference panel for imputation. This allows a more cost effective approach to identifying 
all variants in the specific study population. An additional approach is to capitalize on 
GWAS identification of disease-associated loci and limit deep sequencing to those 
regions. This approach has been used to expand the pool of known associated variants 
in multiple diseases, including IBD [399], RA [397] and SLE [394, 400]. Another 
approach is the combination of low-coverage sequencing data with a traditional GWAS 
approach results in an increased effective sample size and a corresponding increase in 
statistical power [401].  
However, even the most comprehensive genetic study will still be limited in the 
possible conclusions by the nature of the data available for each test subject [402]. This 
has been appreciated and more recent studies combine comprehensive clinical 
information for each subject to look beyond overall disease risk in an effort to identify 
genetic associations with specific phenotypes or disease subtypes [403, 404]. 
Functional annotation of the implicated genetic variants remains one of the key steps in 
assigning causality to a variant. A recent review suggested a workflow for functional 
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annotation including, amongst others, high-throughput expression analysis using 
various expression vectors, functional assays such as detecting changes to protein 
folding, trafficking within the cell, alteration of protein-protein interactions, or finally, 
more specialized functional assays specific for the protein of interest [405]. 
 
Epigenetic data and the ENCODE project: overview and applications 
The Encyclopedia of DNA Elements (ENCODE) project is an effort to catalogue 
all functional elements within the human genome [406]. Amongst the functional 
elements being captured are RNA translated regions, TF-binding sites, chromatin 
structure and DNA methylation sites. By identifying functional elements of the genome, 
not only do we gain a greater understanding of what is encoded in our DNA, but it also 
permits the annotation of identified DNA variants with potential to impact these encoded 
epigenetic functional elements. Some of the potential advancements and inherent 
challenges of combing ENCODE data with GWAS data are reviewed in [407]. Of note, 
one of the greatest challenges remains the successful integration of the data. This 
includes development of new analytical tools and will necessarily include collaborations 
between teams from diverse disciplines. 
One application of the ENCODE database is to reduce the list of potential causal 
variants at a locus by identifying the plausibly functional allele. Schaub et al. [408] 
describe an approach to identifying possible functional candidates. Candidate variants 
in a locus are aligned with the epigenetic data obtained from ENCODE. Variants are 
scored based on the number of overlapping functional annotation tracks, including 
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DNase hypersensitivity, ChIP-seq and e-QTL data. Variants that fall in regions enriched 
for markers of epigenetic regulation that are in high LD with the lead SNP are thus 
flagged as potential candidates for causal variants. 
Epigenetic marks have been used successfully to characterize cancer cell lines 
[409]. By cataloguing the variation in both methylation and DNaseI hypersensitivity 
across the entire genome, the researchers were able to identify a signature that was 
unique to cancer cell lines. Furthermore, the epigenetic elements within the signature 
significantly overlapped with known cancer-associated genomic variants. This study 
emphasizes the power inherent in the growing body of epigenetic data to identify 
regions of epigenetic variability and their overlap with disease-associated genomic 
variants.  
 
Leveraging RNA-seq to more fully understand sequence variation  
The next level of information that would help refine the genetic associations in a 
disease specific manner would be expression data. RNA-seq is a powerful method 
allowing analysis of both overall expression and specific variations in exon usage. By 
combining RNA-seq data with comprehensive genotyping data, genotypic variants 
associated with specific expression patterns can be identified. This approach can be 
especially powerful when RNA-seq is performed on multiple cell types from each 
individual subject. 
For example, researchers recently performed an RNA-seq analysis of cord blood 
containing hematopoietic precursors identified a novel transcription start site and novel 
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exon for NFIB, which they called NFIB-S. The novel, shortened form of NFIB was 
restricted to hematopoietic lineages, unlike the longer, canonical isoform, NFIB-L, which 
is broadly expressed across many tissues. By using both NFIB-S and NFIB-L in 
knockdown and overexpression experiments, they were able to show that NFIB-S plays 
a specific role in the development of megakaryocytes [410]. This study underscores the 
power of using RNA-seq to identify in a more thorough and complete manner differential 
gene expression, including alternative splice events, in specific cellular populations. 
Applying a similar analysis to RNA-seq data obtained from sorted lymphocyte subsets 
from SLE-patient and control populations, for whom genotypes are known, would allow 
a much more complete analysis of specific expression changes associated with SLE 
genotypes.  
Alternative splicing of mRNA is a specific example of expression modulation at 
the mRNA level. Splice variation for individual genes has been shown to occur for nearly 
all genes and often occurs between different tissue types [411]. RNA-seq has been 
successfully used to quantify alternative splicing [412] and this technique has been 
leveraged to investigate the functional relationship between genetic risk and disease 
manifestations. In particular, alternative splicing has been shown to play a role in the 
development of autism spectrum disorders [413]. Alternative splicing has also been 
identified in monocytes from SLE patients when compared to healthy controls [414]. 
Two recent studies highlight the application of RNA-seq to lupus genetics and 
provide some guidance as to how a similar study might be done with PXK. Stone et al. 
examined alternative splicing of IRF5; identifying both a unique transcript signature in 
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subjects with SLE, which is associated with an IRF5 lupus-risk haplotype, in addition to 
demonstrating a difference in the biochemical stability of the various IRF5 isoforms 
[415]. One of the advantages of RNA-seq is the unbiased approach to variant 
identification. By applying next-generation sequencing to the cDNA as opposed to the 
traditional approach utilizing molecular cloning, a much greater number of clones can be 
isolated, greatly increasing the ability to detect transcribed isoforms. By using this 
unbiased approach, they were able to identify not only unique transcripts in patients with 
lupus, but were also able to identify a unique signature of 4 transcripts that were found 
most frequently in patients carrying the previously reported [388] IRF5 H2 risk 
haplotype. 
 Combining genotype information with expression data such as RNA-seq would 
provide a powerful platform for identifying potential causal variants, but would still fall 
short of fully validating the impact of any given single variant on the RNA-seq-defined 
phenotype. The first step in validation would be replication of the results using a 
different approach, such as real-time PCR, to replicate the findings. Cell lines could be 
identified that carry the risk and non-risk variant and then real-time PCR could be 
performed to validate a change in overall RNA expression for instance, and the 
subsequent impact on protein expression and function. While this is an important step in 
the validation process, more powerful strategies could further demonstrate the impact of 
an individual variant. One such strategy would be to directly mutate the identified base 
in a single cell line to both the risk and non-risk genotype. The strength of this approach 
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would be the normalization of any other background genetic or epigenetic modifiers on 
the phenotype. 
 
CRISPRs as Tools for Validation and Therapy 
Single base mutation in a cell line can has been achieved in multiple ways, but 
the CRISPR/Cas9 system has been shown to provide many advantages including the 
ability to be used in many immune cells given their utilization of viral transduction for 
introduction into the cell, and the ability to customize the insert to introduce a single 
base change, which is an important validation of the impact of potential causal SNP 
[416]. Another advantage of CRIPRs is that they can be used to generate the genotype 
of interest even with non-exomic mutations [417]. CRISPRs have been used to knockout 
genes [418], enhancer regions identified in GWAS [419], and have the potential to be 
used to introduce point mutations for verification of genetic association studies. They 
have also been used to successfully generate mice with multiple genetic mutations in 
one step [420]. 
In addition to serving as a tool to validate causal mutations, CRISPRs also have 
great promise as gene therapy. CRISPRs have been used to successfully repair the 
dystrophin gene in mdx mice, a model of Duchene’s Muscular Dystrophy [421], and 
have been used to correct point mutations in cells derived from patients with sickle cell 
disease [422]. They have also been used to target multiple genes simultaneously in 
primates [423]. 
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Another consideration is the impact of the phenotype identified by RNA-seq on 
disease pathobiology. The identified expression change and the specific cell type in 
which it occurred would obviously guide these experiments. An example of how this is 
being done is exemplified by a recent study that analyzed the state of the whole 
genome methylation status during B cell development [424]. They utilized 6 different 
human B cell populations from both peripheral blood and bone marrow samples, 
assessing the methylation state of the entire genome in each B cell population. They 
were able to show that methylation status, which is an indicator of areas of active 
transcription, occurs most frequently in naïve or precursor cell types, and that the lowest 
levels of methylation were found in terminally differentiated cell types, such as 
plasmacytes. Of note, there were unique patterns of methylation of CpGs between the 
various subsets, highlighting the importance of epigenetic regulation to the 
developmental stage of the cell. This study underscores the potential complexity in 
studying the impact of a candidate variant in a biological context. By looking at the 
impact of a given variant on epigenetic modifiers in only one population, it could be easy 
to miss a change that might be unique to another cellular population in an alternate 
developmental pathway. 
 
Utilization of animal models in understanding the PXK locus 
A further step in validating a potential causal variant would be to study the impact 
of that specific variant in an animal model of the disease. By using the aforementioned 
techniques, animals carrying both the risk and non-risk genotype in an otherwise 
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identical genetic/epigenetic environment could be generated, allowing the study of the 
impact of the specific variant on cellular function in vivo. The strength and importance of 
such an approach would be the ability to analyze the effect of a variant in the context of 
an intact system. In addition, perturbations to the system that would lead to a phenotype 
in vivo that might possibly be undetected in an in vitro setting (such as cell-cell 
interactions), could now be assessed. 
We attempted to generate PXK knockout mice using ES cells carrying loxP sites 
allowing both germline knockout and cell type specific conditional knockout mice. 
Utilizing embryonic stem (ES) cells purchased from the International Mouse 
Phenotyping Consortium, part of the European Conditional Mouse Mutagenesis 
Program [425], we arranged for the injection of the ES cells into a carrier mouse 
resulting in the production of one chimeric mouse carrying the targeting construct. From 
our single chimeric male we generated nearly 200 pups, none of which carried the 
construct as a germline mutation. Unfortunately, the chimeric founder died before 
producing offspring carrying the germline construct. Given that we did not know the 
exact causal variant in the PXK locus, but we hypothesized that PXK was the effected 
gene, we planned to generate both germline knockout mice and a parallel mouse line 
capable of conditional knockout of PXK in specific cell types. 
As we found a clear link between PXK and BCR internalization following PXK 
knockdown with shRNA, generating an animal model would provide valuable 
information. Animal experiments would focus first on replicating this result in vivo. We 
would cross our PXK conditional knockout mice carrying loxP sites flanking exons 6 and 
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7 of PXK with CD19-cre mice [426], which would result in cre expression only in CD19+ 
B cells, leading to deletion of the floxed exons of PXK and functional PXK deletion in B 
cells. B cells would be isolated and BCR internalization would be measured as 
described previously. We anticipate that tissue-specific PXK deficiency would lead to a 
similar decrease in BCR internalization as we saw in human immortalized B cell lines. 
Further experiments would focus on defining the functional consequences of PXK 
depletion within the context of animal models of SLE. The initial animal model we would 
utilize is the pristane-induced model of SLE. While there are numerous spontaneous 
mouse models of lupus, the advantage of using the pristane model would be ease of 
induction. We could utilize the existing mice that had been generated for the previous 
described experiments without the need to backcross into one of the strains with 
spontaneous lupus.  
Intraperitoneal pristane injections result in autoantibody production similar to that 
found in human lupus [427, 428]. In addition, these animals develop several clinical 
features similar to human lupus including lupus nephritis and lupus arthritis [429]. Our 
experiments would focus on quantifying disease following pristane-mediated induction in 
CD19-cre/PXK-flox mice. We would quantify disease by looking at autoantibody 
production including ANA and dsDNA production and by quantifying glomerulonephritis 
[430]. We anticipate that PXK-knockdown would result in protection from disease as the 
disease-associated genotype in our human study is protective. 
 
Leveraging the Data with Complex Traits 
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Complex traits are by their very nature difficult to analyze and assess. A complex 
trait is a trait that is dependent on interactions between multiple molecular factors, 
including environmental and behavioral modification. Mendalian traits, in contrast, are 
those that can be explained by variation at a single genetic allele and thus follow 
Mendalian patterns of inheritance. Given the multitude of potential interactions 
underlying the characteristics of a single complex trait, it is apparent that working toward 
an understanding of these interactions and their influence on the manifestation of that 
trait will require immense coordination of large data sets and integration of the data in 
novel ways. In the current –omics era, with the plethora of large datasets emerging from 
the quantification of an expanding number of cellular characteristics, we are continuing 
to increase our capability to better understand the consequences of these interactions. 
One of the next challenges will be to move beyond studies focused on single 
data types to those that utilize all available data, leveraging as much of the available 
data as possible to build more complex and complete models of the actual relationship 
between inherited genetic variation and the phenotypic manifestation of complex traits. 
The importance of looking at multiple types of data instead of focusing on one single 
data type is illustrated in the above review with a hypothetical example using a breast 
cancer model. A similar example could be made for lupus. 
As we described in our earlier review [128], many of the genes so far associated 
with lupus participate in B cell signaling pathways.  As we are able to leverage this 
information and integrate it with the emerging data from epigenetics [431], including 
DNA methylation [432, 433], expression data such as eQTLs [377], comparison to other 
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autoimmune diseases [434], and more, patterns will emerge that can be used to drive 
not just discovery, but treatment as well. A recent example of this approach 
exemplifying the potential inherit in combining multiple types of data is given by Okada 
et al. [435] for RA. In this study, they successfully combine, amongst other data, a large 
GWAS of greater than 100,000 individuals, eQTL analysis, pathway-based analysis, 
epigenetic data available for the loci, overlap between identified genes and genes with 
previously described immune functions, and genes with known targeted drugs, to 
prioritize and validate existing and newly identified associated genetic variants. In 
addition, they also identify newly associated genes with known target drugs already in 
use in other diseases as potential novel drugs that can be trialed in patients with RA. 
Part of the current difficulty is that there are changes that we may not even be 
able to detect by observing only part of the available data. Patterns may emerge 
through the integration of multiple datasets that are not visible in the single data sets 
alone 
 
Further Exploration of BCR signaling 
One of the main modifiers of BCR signaling is the duration of time the BCR-
antigen complex spends on the B cell surface. As BCR internalization has been shown 
to attenuate signaling, molecules that alter the rate of BCR internalization are also likely 
to alter the magnitude or duration of BCR-antigen induced signaling. 
As both PXK knockdown and SLE-associated variants in PXK are associated 
with the rate of BCR internalization following BCR crosslinking, we hypothesize that 
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BCR signaling will be decreased in a similar manner. In order to test this hypothesis, we 
would first measure the impact of the SLE-associated risk variants in the PXK locus on 
constituents of the BCR signaling pathway; namely Ca2+ signaling and second 
messenger phosphorylation. Secondly, we would measure the potential of PXK to 
impact antigen presentation. In addition, changes in BCR internalization may affect BCR 
trafficking within the cell. 
 
Calcium signaling following BCR crosslinking 
For the first experiments focused on immediate signaling consequences, cell 
lines containing the most highly associated risk variant or not would be treated with anti-
BCR as performed previously in the BCR-internalization assays. Cells would then be 
assayed via flow cytometry and western blot analysis for phosphorylation of second 
messenger molecules, including Lyn, Syk, which are early in the signaling cascade. 
Ca2+ mobilization experiments would be run in a similar but slightly different manner. 
The same cell lines would be used, but cells would be loaded with Indo-1 and the 
405/480 nm emission ratio monitored via flow cytometry. The emission ratio of Indo-1 
shifts from about 475 nm without Ca2+ to around 400 nm in the presence of Ca2+. Thus 
an increase in the 405/480 nm ratio is a reliable indicator of Ca2+ levels [436]. Cell would 
be loaded with Indo-1 for 30 min at 37 deg, then a baseline ratio measured on a flow 
cytometry. Cells would then be crosslinked as described above and the 405/480 nm 
ratio monitored for 60 min to measure Ca2+ flux. As our hypothesis is that the delay in 
BCR internalization leads to a decrease in BCR-dependent signaling, we would 
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anticipate that both Ca2+ flux and second messenger phosphorylation will be decreased 
following PXK knockdown and in those cell lines carrying the SLE-associated allele. 
This would suggest that PXK facilitates BCR signaling at that the SLE-association in the 
region may be protective by decreasing B cell activity. 
 
Antigen presentation by stimulated B cells  
BCR internalization does not only affect BCR signaling however. It has also been 
shown to have an impact on antigen presentation by the B cell [437, 438]. It may be that 
the change in BCR internalization we observe in cell lines carrying the SLE-associated 
variant at the PXK locus and following PXK knockdown may also lead to changes in 
BCR-mediated antigen presentation. In order to determine the relationship between 
PXK and B cell antigen presentation, we would utilize transgenic murine B cell lines in 
which we would manipulate PXK. The M12g4Rd B cell line has been transfected with a 
BCR specific for the hapten PC [371, 439]. We would manipulate PXK expression in 
these cells either using virally transfected shRNA to decrease expression, as we have 
done previously in LCLs (Chapter 3, Figure 7), or by using the same transfection system 
to introduce exogenous PXK, resulting in increased protein levels. Following 
transfection, cells would be stimulated with PC-Ova (either the SIINFEKL or 
ISQAVHAAHAEINEAGR peptide), and antigen presentation measured by co-culturing 
PC-ova stimulated cells with ova specific DO.11.10 transgenic T cells. Activation of the 
PC-ova specific T cells would reflect surface antigen presentation by the M12g4Rd B 
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cells. Alternatively, T cell activation following antigen presentation could be quantified by 
determining the amount of IL-2 in the supernatant. 
 We hypothesize that as shRNA mediated knockdown of PXK leads to a decrease 
in BCR internalization that we will observe a decrease in antigen presentation by the 
M12g4Rd B cells following PXK knockdown. This would be evidenced by either a 
decrease in tetramer staining or a decrease in IL-2 amounts following stimulation with 
PC-Ova.  
 
Intracellular BCR trafficking following BCR crosslinking 
Alternatively, the delay in BCR internalization we have observed may instead 
lead to a change in the subcellular destination of the BCR-antigen complex. Changes in 
subcellular localization of the BCR can lead to changes in the nature of the signal [437]. 
In order to investigate the impact of PXK on the subcellular localization of the BCR, we 
would measure colocalization between the BCR and markers of intracellular 
compartments involved in BCR internalization. We would again utilize the LCLs derived 
from SLE patients and controls with known risk/nonrisk genotypes at the SLE-
associated PXK locus and shRNA-mediated PXK knockdown in LCLs. To determine 
changes in BCR trafficking following internalization, cells would be crosslinked as 
previously described and then antibody stained in order to visualize the intracellular 
compartments. Antibodies associated with intracellular locations include EEA1 (early 
endosome) and LAMP1 (late endosome/lysosome). By measuring the colocalization 
between the BCR and intracellular markers over time following BCR crosslinking, we 
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can quantify the change in colocalization and therefore subcellular localization of the 
BCR following PXK manipulation. 
 
Regulation of B cell survival and activation through the BCR 
The BCR-antigen complex fails to enter the late endosome in anergic B cells 
[438]. This disruption in BCR trafficking is hypothesized to prevent the efficient 
presentation of cognate antigen to T cells as the primary site of antigen processing in B 
cells is the late endosome [440]. If the SLE-associated variant in the PXK locus likewise 
disrupts delivery of antigen to the late endosome, either through delayed internalization 
or alteration of the BCR transit through the B cell, this could have profound effects on 
both B cell fate and the subsequent immune response. The delivery of the BCR to the 
late endosome is not only disrupted in anergic B cells, but can actually induce anergy as 
restoration of BCR-antigen complex to the late endosome actually reverses anergy 
[438]. Additionally, rapid BCR internalization has been shown to be inhibitory in B cells, 
leading to downregulation of B cell signaling [441]. BCR trafficking is a key modulator of 
antigen presentation [442], [443]. 
BCR internalization is also an important regulator of BCR signaling. Blocking 
BCR internalization changes the gene activation profile following BCR crosslinking 
[355]. Phosphorylated BCR remains on the cell surface to form the signalsome 
responsible for the afferent signaling pathway. This signaling begins with 
phosphorylation of ITAMs on Igα leading to recruitment of SFTKs and signal cascade 
induction. However, ITAM motifs on Igα and Igβ not only serve as the site of recruitment 
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of second messenger molecules following phosphorylation of these motifs [444-446], 
but are also important for receptor internalization [447]. The ITAM motif is also 
recognized by AP2, which helps regulate receptor internalization through clathrin-coated 
pits [448]. Therefore, endocytosis of BCR complexes is dependent upon ITAMs that are 
not phosphorylated. So BCR internalization attenuates BCR signaling not by 
internalization of actively signaling (phosphorylated) receptor complexes, but instead by 
reducing the number of available receptors on the cell surface [336]. 
Following internalization, BCR-antigen complexes are sorted through the early 
endosome to arrive in the late endosome. This sorting is thought to be facilitated by the 
endosomal complex required for transport (ESCRT), as occurs in other APCs. The 
ESCRT machinery functions primarily by recognizing ubiquitin modifications of receptors 
[449, 450]. Crosslinking of BCR on the cell-surface leads to ubiquitination of the 
receptor complex and delivery to the ESCRT pathway, mediated at least in part by the 
ubiquitin ligase, Cbl-b [451]. 
Activation of lymphocytes typically requires at least two signals. For T cells, the 
integration of these two signals occurs on the cell surface through binding of co-
stimulatory receptors on the cell surface of APCs [452]. B cells also require two signals, 
but unlike in T cells, the signal integration occurs instead in the late endosome [437, 
453]. Entry into the MIIC facilitates antigen processing and MHC class II loading and is 
regulated by BCR signaling [454]. 
High affinity autoreactive B cells clones are eliminated early in B cell 
development through clonal deletion and receptor editing [101, 103, 455-457]. However, 
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in normal controls, up to 20% of mature naïve B cells are autoreactive, while in patients 
with SLE, that number increases to as many as 50% [458]. Notably, this large pool of 
self-reactive B cells does not regularly contribute to the humoral immune response. 
Instead, these autoreactive cells largely persist in the body in an inactive state of anergy 
[459-461], which is thought to be the means by which most autoreactive B cells are 
silenced in the periphery [462].  One mechanism by which anergy is thought to inhibit 
cellular activation is through the exclusions of both the BCR and the co-signaling 
activators such as TLR9, from the MIIC [438]. This endocytic block arrests both TLR9 
and the BCR just outside the late endosome.  Restoration of TLR9 and the BCR to the 
late endosome overcomes this block. 
BCR surface expression decreases in the context of antigen recognition during B 
cell development [463]. IgM downregulation is proportional to the amount of antigen 
recognition. Interestingly, these cells (with low BCR surface expression) are not 
eliminated but persist in the mature B cell pool. Furthermore, anti-ANA reactive B cells 
are overrepresented in this population, leading to the hypothesis that these cells may 
represent a source for pathogenic antibodies in autoimmune disease [463]. 
 
Potential Consequences of Delayed BCR Internalization 
 We found that the SLE associated variants at the PXK locus lead to a decrease 
in BCR internalization. Given that BCR internalization is linked with both the B cell 
activation state and delivery of antigen for processing, there are multiple potential 
consequences of these variants. Firstly, the decrease in BCR internalization could lead 
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to an increase in survival signals early in development, resulting in potential 
autoreactive cells that are a normal part of the dormant pool in the periphery now 
persisting with a lower threshold for activation. These cells would usually be found in a 
dormant state in the periphery due to BCR downregulation and dampening of BCR 
signaling. Now however, with a decrease in BCR internalization, BCR signaling may be 
increased, leading to a lower threshold for activation and an increase in activation of 
autoreactive clones. One way to test this hypothesis would be to look simply at 
peripheral B cell activation states in individuals striated according to the SLE-associated 
risk allele at the PXK locus. We would expect that individuals carrying the allele 
associated with delayed internalization would have an increased population of activated 
B cells, using measures such as cell-surface expression of CD27 or other markers of B 
cells activation. 
 Another possible mechanism, however, could be an alteration of delivery of 
antigen to the MIIC with consequences to both cellular activation and/or antigen 
presentation. As stated earlier, delivery of the BCR is an important step in the regulation 
of anergy. Presumably, a decrease in BCR internalization would lead to a delay in BCR 
delivery to the MIIC. This could lead to both a disruption of antigen presentation and 
also to a reduction in overall activation, pushing the cell toward anergy. 
 
Summary and Conclusion 
During our analysis of the PXK locus, we streamlined our data analysis of SNP 
genotyping data sets. We developed a systematic approach, integrating rigorous 
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statistical testing of genetic association, complete evaluation of the target locus given 
the available data, imputation to fully exploit the publically available data, followed by 
targeted methods aimed at identifying underlying genetic structure at the locus. We 
used this approach to successfully confirm disease association at multiple loci, including 
IRF5 [394], PXK [464], and ETS1 [465].  As we adopted a unified approach to each data 
set, utilizing similar analytical approaches for each, we then could develop streamline 
our analysis across all data sets. The analysis method is described in the 3rd chapter of 
this dissertation. By using the same analytic approach for each locus, we could join the 
analysis tools using simple computer programs to facilitate processing from start to end. 
We were also able to analyze multiple potential genetic models at once by processing 
the different scenarios simultaneously, again facilitated by simple computer programs. 
By streamlining the initial analysis, we are able to spend less time on identifying regions 
of association, and can instead focus on verification and following up potential biological 
findings. 
At the PXK locus, we confirmed the SLE association and identified the region of 
the locus most likely to contain the variant responsible for the association. In addition, 
we were able to show that the SLE association at the locus was also associated with a 
delay in BCR internalization from the cell surface. This is the first time that the function 
of the B cell receptor is associated with SLE-risk variants. We also showed that PXK 
levels in the cell correlate with BCR internalization. This novel finding is especially 
intriguing given the limited data supporting a role for PXK in receptor trafficking within 
the cell [141]. 
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BCR internalization is necessary for the transportation of antigen to the MIIC to 
be processed and loaded onto MHCII molecules for recruitment of T cell help. BCR 
internalization also reduces the strength of the signalsome by reducing the number of 
unphosphorylated BCR receptors on the cell surface, thus dampening the overall 
afferent signal strength. In addition, the MIIC is the location of the integration of the co-
stimulatory activation signal and thus reduction of BCR delivery to the MIIC promotes 
anergy. 
Given these described consequences of BCR internalization, changes in BCR 
internalization may have multiple consequences. Delay in BCR internalization may 
result in delay of MIIC antigen delivery, and consequently attenuation of recruitment of T 
cell help. Delay in arrival of BCR to the MIIC may also result in enhancement of the 
propensity toward anergy development. Alternatively, the increase in surface BCR 
expression due to delayed internalization may lead to enhancement of signalsome 
activation and B cell activation secondary to BCR complex ITAM phosphorylation. 
It is therefore difficult to predict the exact consequences that PXK-mediated 
modulation of BCR internalization may have on B cell signaling within the context of 
lupus pathogenesis. However, BCR internalization is central to B cell development, 
survival, and modulating the B cell repertoire in the periphery. Genetic variants that lead 
to alterations in BCR internalization, regardless of the exact mechanism, have the 
potential to have a profound effect on the development of autoimmune disease. 
It is the combination of all the possible mechanisms- common variants, rare 
variants, gene-gene interactions, gene-environment interactions, and epigenetics, 
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coming together to form a combined genetic contribution to disease. The exact result of 
any given mutation in a specific subject will depend on their background genetic liability 
and the strength of that specific mutation within the context of that liability. A mutation 
may put one person over the disease threshold, but may just move another individual 
closer to that threshold while remaining healthy [386]. Our understanding of lupus and in 
particular, the SLE-association at the PXK locus, will be greatly enhanced in the coming 
years through the push for data integration. This will likely lead to not just a more 
complete picture of disease pathology, but also to potential targets of intervention. 
Treatments targeting the activation potential of B cells by modulating BCR 
internalization are likely to have a profound effect on B cell mediated autoimmune 
diseases. 
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